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A B S T R A C T
Background
Pneumonia is an important cause of mortality in intensive care units (ICUs). The incidence of pneumonia in ICU patients ranges between
7% and 40%, and the crude mortality from ventilator-associated pneumonia may exceed 50%. Although not all deaths in patients with this
form of pneumonia are directly attributable to pneumonia, it has been shown to contribute to mortality in ICUs independently of other
factors that are also strongly associated with such deaths.
Objectives
To assess the eects of prophylactic antibiotic regimens, such as selective decontamination of the digestive tract (SDD) for the prevention
of respiratory tract infections (RTIs) and overall mortality in adults receiving intensive care.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2009, issue 1), which contains the
Cochrane Acute Respiratory Infections (ARI) Group's Specialised Register; MEDLINE (January 1966 to March 2009); and EMBASE (January
1990 to March 2009).
Selection criteria
Randomised controlled trials (RCTs) of antibiotic prophylaxis for RTIs and deaths among adult ICU patients.
Data collection and analysis
At least two review authors independently extracted data and assessed trial quality.
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Main results
We included 36 trials involving 6914 people. There was variation in the antibiotics used, patient characteristics and risk of RTIs and mortality
in the control groups. In trials comparing a combination of topical and systemic antibiotics, there was a significant reduction in both RTIs
(number of studies = 16, odds ratio (OR) 0.28, 95% confidence interval (CI) 0.20 to 0.38) and total mortality (number of studies = 17, OR
0.75, 95% CI 0.65 to 0.87) in the treated group. In trials comparing topical antimicrobials alone (or comparing topical plus systemic versus
systemic alone) there was a significant reduction in RTIs (number of studies = 17, OR 0.44, 95% CI 0.31 to 0.63) but not in total mortality
(number of studies = 19, OR 0.97, 95% CI 0.82 to 1.16) in the treated group.
Authors' conclusions
A combination of topical and systemic prophylactic antibiotics reduces RTIs and overall mortality in adult patients receiving intensive care.
Treatment based on the use of topical prophylaxis alone reduces respiratory infections but not mortality. The risk of resistance occurring
as a negative consequence of antibiotic use was appropriately explored only in one trial which did not show any such eect.
P L A I N   L A N G U A G E   S U M M A R Y
Antibiotics to help reduce mortality and respiratory infections in people receiving intensive care in hospital
Infections acquired in intensive care units (ICUs) are important complications of the treatment of patients with very severe diseases who
need ventilation (mechanical breathing support). Some people will die because of these infections. Considerable eorts have been made to
evaluate methods for reducing this problem; one of these involves the use of antibiotics administered as preventative intervention, usually
referred to as selective decontamination of the digestive tract (SDD). This review includes 36 studies involving 6914 patients treated in
ICUs to investigate whether the administration of antibiotics prevents the development of infections. Antibiotics were administered in two
dierent ways. In some studies antibiotics were applied both directly to the oropharynx via a nasogastric tube (topical) and intravenously
(systemic). In other studies they were applied only topically. Our results show that when patients received the combination of topical plus
systemic antibiotics there were less infections and deaths. When patients received only topical treatment there were less infections but
the number of deaths was not changed. Although this treatment seems to work it is not widely used in clinical practice because there is
concern about the possible development of antibiotic resistance (that is, bacteria become unresponsive to drugs).
Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care (Review)
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B A C K G R O U N D
Description of the condition
Infections acquired in the intensive care unit (ICU), especially
pneumonia, are important complications of the treatment of
critically ill patients, increasing morbidity and mortality. The
incidence of pneumonia has been reported to vary from 7% to more
than 40% in ICU patients (Chevret 1996; Fagon 1996). The mortality
rate for patients with ventilator-associated pneumonia (VAP) may
exceed 50%. Although not all deaths in patients with pneumonia
are directly attributable to pneumonia, it has been shown to
contribute to ICU mortality, independently of other factors that
are also strongly associated with deaths in these patients (Fagon
1996). In a case-controlled study an increase in mortality of 27%
attributable to pneumonia was evidenced in ventilated patients
(Fagon 1996).
Description of the intervention
Considerable eorts have been made to evaluate methods for
reducing respiratory tract infections (RTIs). One strategy involves
the use of selective decontamination of the digestive tract (SDD).
Dierent SDD protocols have been used in dierent trials and
investigators oNen disagree on which is the most appropriate
definition of SDD. Traditionally, SDD indicates a method designed
to prevent infection by eradicating and preventing carriage
of aerobic, potentially pathogenic micro-organisms from the
oropharynx, stomach and gut. It consists of antimicrobials applied
topically to the oropharynx through a nasogastric tube. In some
trials systemic antibiotic therapy has been added in the first days
aNer the patients' admission to prevent 'early' infections.
How the intervention might work
The use of oral non-absorbable antibiotics was first reported by
Stoutenbeek (Stoutenbeek 1994) in an SDD protocol based upon
a group of multiple trauma patients. The incidence of nosocomial
(hospital-acquired) infection was reduced from 81% to 16% in
a non-randomised comparison with an historical control group.
Further studies tested the eicacy of SDD in ICU patients, with
infection-related morbidity as the main endpoint. The results
showed that SDD reduced infection but it was not clear whether
there was a reduction in mortality.
Between 1991 and 2008 nine dierent systematic review and meta-
analyses (D'Amico 1998; Heyland 1994; Hurley 1995; Kollef 1994;
Nathens 1999; Redman 2001; Silvestri 2007; SDD Group 1993;
Vanderbrouk-Gra 1991) on the eect of SDD on RTIs and mortality











6 491 Odds ratio (OR) 0.70 
95% confidence intervals (CI) 0.45 to
1.09
OR 0.12 
95% CI 0.08 to 0.19
SDD Group
1993
22 4142 OR 0.90 
95% CI 0.79 to 1.04
OR 0.37 
95% CI 0.31 to 0.43
Heyland
1994
24 3312 Risk ratio (RR) 0.87 
95% CI 0.79 to 0.97
RR 0.46 
95% CI 0.39 to 0.56
Kollef 1994 16 2270 Risk difference (RD) 0.019 
95% CI - 0.016 to 0.054
Pneumonia 
RD 0.145 
95% CI 0.116 to 0.174
Tracheobronchitis 
RD 0.052 
95% CI 0.017 to 0.087
Hurley
1995
26 3768 OR 0.86 
95% CI 0.74 to 0.99
OR 0.35 
95% CI 0.30 to 0.42
D'Amico
1998
33 5727 Topical plus systemic (16 trials; 3361
pts) 
OR 0.80 
95% CI 0.69 to 0.93
Topical alone (17 trials; 2366 pts) 
OR 1.01 
95% CI 0.84 to 1.22
Topical plus systemic (16 trials; 3361 pts) 
OR 0.35 
95% CI 0.29 to 0.41
Topical alone (17 trials; 2366 pts) 
OR 0.56 
95% CI 0.46 to 0.68
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95% CI 0.52 to 0.93
Medical patients 
OR 0.91 









NA Ventilator-associated pneumonia (VAP) 
OR 0.36 
95% CI 0.28 to 0.46
Silvestri
2007
51 8065 OR 0.8 
95% CI 0.69 to 0.94
NA
 
All studies assessing RTIs confirmed their statistically significant
reduction, though the magnitude of the treatment eect varied
from one review to another probably due to dierent numbers of
studies and inclusion criteria among them. The estimated impact
on overall mortality was less evident.
This is an update to the previous version published in The Cochrane
Library which included trials published up to 2003.
O B J E C T I V E S
To determine whether antibiotic prophylaxis reduces RTIs and
overall mortality in adult patients treated in ICUs.
Specifically, the main question leN unanswered by existing
randomised controlled trials (RCTs) and previous meta-analyses
was whether dierent forms of antibiotic prophylaxis (that is,
topical antimicrobials or a combination of topical and systemic
drugs) are eective in reducing overall mortality.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs on antibiotic prophylaxis for preventing RTIs and deaths in
adult ICU patients.
Types of participants
Adult patients admitted to an ICU. Studies based on specific pre-
selected types of patients (that is, patients undergoing elective
oesophageal resection, cardiac or gastric surgery, liver transplant
or suering from acute liver failure) were excluded because these
patients need co-interventions that may interact with the main
treatment. Studies where the majority of patients (> 50%) did not
undergo mechanical ventilation for more than 48 hours were also
excluded. The characteristics of excluded studies are reported in
the 'Characteristics of excluded studies' table.
Types of interventions
Available RCTs have been grouped into two categories, defined
according to the type of antibiotic prophylaxis:
1. studies where a combination of systemic and topical antibiotics
was tested against no prophylactic treatment (thereaNer
referred to as 'topical plus systemic versus no prophylaxis'); and
2. studies where the experimental treatment tested was a topical
preparation applied in the oropharynx (thereaNer referred to as
'topical versus control').
For further details about preparation and administration of
antibiotic prophylaxis see the 'Characteristics of included studies'
table.
In this latter category two RCT subgroups have been lumped
together, that is, those where topical antibiotics were tested against
an untreated control group and those where the combination of
topical plus systemic drugs was compared with a protocol based on
a systemic antimicrobial only.
Any topical or systemic antimicrobial combination (that is: type
of drugs) was accepted, because there was no data to assume a
dierence in eect among the considered prophylactic treatments.
This obviously does not mean that all topical and systemic
regimens are truly equivalent, but simply reflects our pragmatic
working assumption.
Types of outcome measures
Primary outcomes
Primary outcome measures considered for this review were RTIs
and overall mortality.
No restriction was made on the type of RTIs considered, or
on the RTIs diagnostic criteria chosen by the trialists. Both
tracheobronchitis and pneumonia were acceptable. Pragmatically,
both primary (diagnosed within 48 hours from admission) and
acquired (diagnosed aNer 48 hours from admission) infections
were considered, even though we used data on acquired infections
(the most appropriate outcome to assess treatment eect) when
both pieces of information were available. Mortality was evaluated
at hospital discharge if this information was provided; otherwise
mortality in ICU was used.
Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care (Review)
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Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2009, issue 1); MEDLINE (January
1966 to March 2009); and EMBASE (January 1990 to March 2009).
MEDLINE was searched using the following search strategy
in conjunction with the Cochrane Highly Sensitive Search
Strategy for identifying randomised trials in MEDLINE: sensitivity-
and precision-maximising version (2008 revision); Ovid format
(Lefebvre 2008). The same strategy was used to search CENTRAL
and adapted to search EMBASE.com (see Appendix 1).
MEDLINE (Ovid)
1 exp Respiratory Tract Infections/
2 respiratory tract infection*.tw.
3 exp Pneumonia/
4 pneumon*.tw.











16 exp Intensive Care Units/
17 icu.tw.







25 (critic* adj ill*).tw.







33 15 and 32
34 Pneumonia, Ventilator-Associated/
35 33 or 34
36 Antibiotic Prophylaxis/
37 exp Anti-Bacterial Agents/
38 antibiotic*.tw.
39 or/36-38
40 35 and 39
Searching other resources
There were no language or publication restrictions. We searched
reference lists of articles from January 1984 to March week 1 2009
and proceedings of scientific meetings from January 1984 to April
2002. We also contacted investigators in the field. We evaluated
other studies listed in previous meta-analyses. We did not make any
formal enquiries through pharmaceutical companies. We stopped
the search for conference proceedings aNer the early phase of this
review in 2002 when we decided that in subsequent updates we will
include new data only if reported in fully published papers.
Data collection and analysis
Selection of studies
Three review authors (LB, EP, SP) independently screened the titles
and abstracts of all the references retrieved by the search strategy.
The full text of relevant studies were assessed independently to
determine whether they met the inclusion criteria. Disagreements
were resolved by discussion with the two review authors (AL, RD).
Data extraction and management
Three review authors (LB, EP, SP) independently extracted data
from all the included studies using an ad hoc extraction form.
Disagreements were solved by discussion with two review authors
(AL, RD).
Assessment of risk of bias in included studies
At least two review authors (LB, EP, SP) independently assessed the
methodological validity of selected trials according to two quality
criteria:
• quality of randomisation procedures ('adequate' versus
'unclear, inadequate or not done' which will be referred
hereaNer as 'not adequate'); and
• blinding of patients and doctors to allocated treatment ('double-
blind' versus 'open').
We resolved outstanding issues by consensus.
Only RCTs were accepted in order to prevent possible selection bias.
Studies including adult patients admitted to an ICU were included.
Studies based on specific pre-selected types of patients (that is,
patients undergoing elective oesophageal resection, cardiac or
gastric surgery, liver transplant or suering from acute liver failure)
were excluded.
Measures of treatment eCect
Crude proportions of RTIs and mortality were our main treatment
end-points. Odds ratios (OR) for each trial and for each outcome
were calculated and they were summarised by using the fixed-
eect model, whereas the random-eects model was used in cases
of statistically significant heterogeneity (P = 0.1). We also computed
the number of ICU patients who need to be treated in order to
prevent one infection and one death. The calculation was based on
the median rates of RTIs and deaths in untreated controls and the
common OR for all trials.
Dealing with missing data
We contacted study investigators in order to obtain data for
intention-to-treat analysis. In 25 out of 36 studies we obtained data
on patients lost to follow-up while for the remaining 11 studies we
relied on published information only.
Data synthesis
Results from the trials were combined using a fixed-eect model
to calculate odds ratio (OR) with 95% confidence intervals (CI) for
Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care (Review)
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dichotomous data. In case of statistically significant heterogeneity
a random-eects model was used.
The number needed to treat to benefit (NNTB) was calculated.
Subgroup analysis and investigation of heterogeneity
Two pre-specified subgroup analyses based on quality criteria were
carried out within the two main groups of RCTs specified above:
• quality of randomisation procedures; and
• blinding of patients and doctors to allocated treatment.
R E S U L T S
Description of studies
Results of the search
Sixty potentially eligible RCTs were identified from the electronic
searches.
Included studies
Thirty-six RCTs were finally included, all of them were published (34
as full reports and two in abstract form). Seventeen RCTs compared
topical and systemic antibiotic treatment versus no treatment or
placebo; 14 RCTs compared topical treatment to no treatment or
placebo; and five trials compared topical and systemic antibiotic
treatment versus systemic antibiotic only.
We included two studies (Gaussorgues 1991; Laggner 1994) among
the 'topical SDD plus systemic antibiotic versus systemic antibiotic
only' group even if their design did not explicitly foresee the use of
systemic antibiotics because all patients in both arms were treated
with systemic antibiotics on admission. Similarly, we included
the Jacobs (Jacobs 1992) study among the 'topical SDD plus
systemic antibiotics versus control' group because more than 90%
of patients received a systemic antibiotic on admission.
The four studies with a three-arm comparison were analysed as
follows. In two studies (Aerdts 1991; Verwaest 1997) the two control
groups were pooled together and compared to the treatment
group. In another study (Lingnau 1997) we split the study into two
comparisons in which two dierent treatment arms were compared
to the same control arm. In one study (Palomar 1997) one of the
two control arms was excluded because patients received only
sucralfate. Another study (Camus 2005) was a four-arm factorial
design in which we considered only two arms comparing antibiotic
prophylaxis versus placebo.
Overall, the total number of patients randomised to either
antibiotic prophylaxis versus placebo or no treatment was 6914.
The final meta-analysis was based upon 36 trials with 37
comparisons.
Two studies (Cerra 1992; Gaussorgues 1991) could not contribute to
the RTIs analysis as they reported the number of episodes of RTIs
and not the number of infected patients. Moreover, one trial (de
Jonge 2003) did not assess RTIs as an endpoint.
Mortality was evaluated in ICU in 24 trials; hospital mortality was
available only for six RCTs; two trials reported mortality in both ICU
and hospital (de Jonge 2003; Georges 1994) and the exact time of
assessment of mortality was not determined in four trials (Cerra
1992; Jacobs 1992; Kerver 1988; Pneumatikos 2002).
Most RCTs included general ICU patients. A few trials included
mostly trauma (Boland 1991; Georges 1994; Lingnau 1997;
Pneumatikos 2002; Quinio 1995; Stoutenbeek 1996; Stoutenbeek
2007) or surgical patients (Cerra 1992; Krueger 2002).
One-hundred percent of patients were mechanically ventilated in
26 studies; this percentage was lower in six trials (Brun-Buisson
1989; Blair 1991; Cockerill 1992; de Jonge 2003; Ulrich 1989;
Winter 1992) and unknown in four (Camus 2005; Cerra 1992;
Finch 1991; Krueger 2002). In Brun-Buisson's study (Brun-Buisson
1989) the percentage of ventilated patients was very low (59%)
probably because the setting of the study included both 'acute' and
'intermediate' areas of a medical ICU.
The percentage of immunocompromised patients was usually
lower than 10%; it was higher only in four trials (Brun-Buisson 1989;
Finch 1991; Gastinne 1992; Laggner 1994). Sucralfate was routinely
used in all patients for stress ulcer prophylaxis in nine trials (Abele-
Horn 1997; Bergmans 2001; Ferrer 1994; Gaussorgues 1991; Jacobs
1992; Krueger 2002; Laggner 1994; Quinio 1995; Verwaest 1997).
In many RCTs only RTIs acquired in ICU (that is, diagnosed aNer
48 hours from admission) were considered. Data on primary and
acquired infections were considered together only in three trials
(Boland 1991; Stoutenbeek 1996; Stoutenbeek 2007). Most studies
(26 RCTs) evaluated only the occurrence of pneumonia, while seven
RCTs also evaluated tracheobronchitis; information was lacking
in three RCTs. Diagnostic criteria diered across trials. Few trial
authors provided quantitative details on the cut-o point used as
positive bacteriological confirmation.
Excluded studies
Twenty-six trials were excluded (see 'Charateristics of excluded
studies' table) (Arnow 1996; Barret 2001; Bion 1994; Bouter 2002;
de la Cal 2005; de Smet 2009; Flaherty 1990; Garbino 2002;
Hellinger 2002; Hunefeld 1989; Jacobs 1995; Lipman 1994; Luiten
1995; Martinez 1994; Martinez-Pellus 1993; Nardi 2001; Rayes 2002;
Rolando 1996; Ruza 1998; Lenhart 1994; Stoutenbeek 2; Schardey
1997; Smith 1993; Tetteroo 1990; Zobel 1991; Zwaveling 2002).
Risk of bias in included studies
Study quality was assessed looking at two criteria. These two
quality criteria were used to perform one-way subgroup analyses
for two treatment comparisons (topical plus systemic versus no
treatment and topical alone versus no treatment) on the two main
outcomes (RTIs and overall mortality).
Allocation
A = adequate; B = unclear; C = inadequate; D = not used.
Allocation concealment was evaluated according to the criteria
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ECects of interventions
RTIs
Results from 33 RCTs including 5697 patients were available for the
analysis on the eects of dierent types of antibiotic prophylaxis
on RTIs. The frequency of RTIs was 19% among treated patients
and 40% among controls in RCTs using a combination of topical
plus systemic antibiotic and 20% and 31%, respectively, in RCTs
testing the eectiveness of topical prophylaxis. Overall, the ORs
were less than 1 in all but two trials (Lingnau 1997; Wiener 1995)
and reached conventional statistical significance (P < 0.05) in 22/34
comparisons.
Since statistically significant heterogeneity was observed, a
random-eects model was used to summarise study results.
Results indicate a strong protective eect in RCTs where the
combination of topical and systemic treatment (OR 0.28, 95% CI
0.20 to 0.38) was tested. A significant protection emerged when
topical prophylaxis was considered (OR 0.44, 95% CI 0.31 to 0.63).
The eect was stronger in RCTs where topical antimicrobials were
tested against no prophylaxis (OR 0.34, 95% CI 0.21 to 0.55). Less
extreme results were observed in trials testing the combination of
topical and systemic antibiotic against systemic prophylaxis (OR
0.79, 95% CI 0.56 to 1.13).
These results indicate that four (95% CI 3 to 5) or seven (95% CI 6
to 12) patients need to be treated to prevent at least one infection,
depending on whether a combination of topical and systemic
treatment or topical antimicrobials alone were tested (assuming,
as baseline risk, the median values of 46% and 27%, respectively,
among control patients).
Regarding the pre-defined subgroup analyses, a statistically
significant dierence in the estimates of treatment eect was only
found for quality of allocation concealment in the topical versus
control comparison.
Mortality
Overall, 36 RCTs including 6,914 patients were available for the
mortality analysis. The mortality was 24% among treated patients
and 30% among controls on RCTs using a combination of topical
plus systemic antibiotic; while it was 26% and 25% respectively
in RCTs testing the eectiveness of topical SDD. The ORs were
less than 1 in 26/38 comparisons but reached conventional
statistical significance in three RCTs (de Jonge 2003; Krueger 2002;
Stoutenbeek 1996); no trial showed a significant harmful eect of
antibiotic prophylaxis.
Regarding mortality no statistically significant heterogeneity was
observed among study results.
Results indicated a statistically significant reduction in mortality
attributable to the use of a combination of topical and systemic
treatment (OR 0.75, 95% CI 0.65 to 0.87). This suggests that 18
patients (95% CI 12 to 36) (assuming a baseline risk of 29%, median
among control patients) need to be treated to prevent one death.
On the other hand, no treatment eect emerged when RCTs testing
topical antimicrobials were analysed (OR 0.97; 95% CI 0.82 to 1.16).
The subgroup analyses produced the following results:
Topical versus control
Allocation concealment: adequate (OR 0.64, 95% CI 0.27 to 1.52),
not adequate (OR 0.99, 95% CI 0.83 to 1.18).
Blind design: double blind (OR 0.99, 95% CI 0.83 to 1.20), open (OR
0.88, 95% CI 0.56 to 1.37).
Topical plus systemic versus no prophylaxis
Allocation concealment: adequate (OR 0.77, 95% CI 0.66 to 0.90),
not adequate (OR 0.67, 95% CI 0.48 to 0.93).
Blind design: double blind (OR 0.63, 95% CI 0.48 to 0.83), open (OR
0.80, 95% CI 0.68 to 0.95).
D I S C U S S I O N
Since antibiotic prophylaxis based on SDD was introduced as a
preventative measure against infection in critically ill patients, it
has remained a controversial intervention (Stoutenbeek 1994). Due
to the lack of a standard protocol and insuicient patient numbers,
it has proved diicult to derive meaningful conclusions from
individual clinical trials. Following initial enthusiasm from results
of early uncontrolled studies and RCTs, antibiotic prophylaxis is
not widely used as a routine treatment in ICUs. Concerns about
the risk of antimicrobial resistance and increased costs are oNen
quoted as important factors preventing its widespread adoption. A
conservative attitude in introducing a new treatment into practice
is understandable as long as doubts about its eicacy exist. Studies
on prevention of VAP in ICU patients are complex, as patients
are heterogeneous, diagnosis of pneumonia is controversial and
outcomes depend upon a variety of factors. Despite the fact
that antibiotic prophylaxis reduces the emergence of RTIs with
remarkable consistency across individual trials, the eect on
mortality was individually statistically significant in only three
trials. An historical examination of review articles and editorials in
this area indicates that for many years it was not fully realised that
this could have been due to the small sample sizes of individual
studies.
The meta-analysis reported here combines data across several
studies in order to estimate treatment eects with more precision
than is possible in a single study. The main limitation of this type
of pooled analysis is that the patient population, the antibiotic
regimen and the outcome definitions are not the same across
studies. Nonetheless, we believe that it provides the best global
picture of the eectiveness of the intervention despite some recent
criticisms on the quality of primary studies and their combination
(van Nieuwenhove 2001) which we feel we have convincingly
addressed (Liberati 2001). Compared to the other six published
meta-analyses (Heyland 1994; Hurley 1995; Kollef 1994; Nathens
1999; SDD Group 1993; Vanderbrouk-Gra 1991) we decided in our
previously published review (D'Amico 1998) to analyse separately
trials testing a combination of systemic and topical antibiotics and
those testing topical antimicrobials. Though there is no consensus
on the best way to classify antibiotic prophylaxis regimens,
eventually it seemed more appropriate to consider the two groups
of trials as two distinct approaches to antibiotic prophylaxis. This
decision was made a priori, independently of knowing their results.
As already shown in our previous review (D'Amico 1998) and
confirmed in this update, both types of prophylaxis have a strong
protective eect on RTIs - with the eect being more marked
when patients are treated with a protocol using topical plus
systemic antibiotics. This eect looks consistent in all subgroup
Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care (Review)
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analyses, regardless of study design (adequate / not adequate
allocation concealment, double-blind / open design). Overall, these
results appear convincing even though it is acknowledged that
no diagnostic test or procedure is ideal to diagnose RTIs in ICU
patients.
More importantly, this updated review confirms that the use of
a combination of topical and systemic antibiotics reduces overall
mortality significantly. This treatment eect looks important from a
clinical and public health point of view (in terms of the therapeutic
implications for the care of ventilated patients in ICUs) and is also
relevant from the scientific standpoint, as it suggests the future
directions that research in this field should take.
Publication bias is unlikely to have influenced our results
because we made a thorough eort to trace unpublished
studies and because the vast majority of trials did not show
statistically significant reduction in mortality on their own.
Moreover, inspection of the relevant funnel plot for overall
mortality reduction in patients receiving the combined treatment
(see additional analysis, Figure 1) does not provide evidence of
publication bias. Finally, if one ranks studies by their size, larger





A U T H O R S '   C O N C L U S I O N S
Implications for practice
This systematic review indicates that a protocol testing a
combination of topical and systemic antibiotics reduces the
occurrence of RTIs and overall mortality. These results were initially
obtained in an individual patient meta-analysis reported elsewhere
(D'Amico 1998), which we have now updated using data reported in
trials published between 1999 and 2007. The yield of the treatment
expressed in terms of patients needed to be treated to prevent one
infection and one death is substantial - 4 and 18 respectively - and
compares very favourably with several interventions largely used
in clinical practice. Though 11/17 trials used an identical regimen,
including polymyxin, tobramycin and amphotericin as the topical
combination and cefotaxime as the systemic component (Abele-
Horn 1997; Blair 1991; de Jonge 2003; Ferrer 1994; Hammond 1992;
Jacobs 1992; Kerver 1988; Palomar 1997; Rocha 1992; Stoutenbeek
1996; Stoutenbeek 2007), this review does not allow a unique
regimen to be recommended. The use of a prophylaxis testing
topical antimicrobials is, on the other hand, not warranted by
available data.
Results of this review should be carefully considered by those
who have been sceptical about the eectiveness of antibiotic
prophylaxis, mostly on the grounds of a potentially harmful eect in
terms of antibiotic resistance (Collard 2003). Moreover, important
new information has become available in a large randomised trial
(de Jonge 2003) that was the first to be formally designed to reliably
assess the occurrence of antibiotic resistance by randomising
ICUs rather than patients and monitoring the units for more than
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two years aNer the inception of treatment use: de Jonge et al
reported that no patients were colonised with meticillin-resistant
staphylococcus aureus, only 1% was colonised with vancomicin-
resistant enterococcus and in 16% and 26% (in SDD and control
patients, respectively) colonisation with gram negative bacteria
resistant to ceNazidime, ciprofloxacin, imipenem, polymyxin E and
tobramycin occurred (de Jonge 2003).
We believe that insuicient data on cost-eectiveness and
antibiotic resistance should stimulate future research rather than
preventing the adoption of a seemingly eective intervention. The
impact of antibiotic prophylaxis on costs has so far been evaluated
only rarely and, more importantly, in an improper way (the analysis
being essentially based on comparisons of lengths of stay and
computation of charges due to antibiotic use). A proper economic
analysis is, on the other hand, likely to be diicult in a highly
specialised setting such as an ICU, given that it is hard to quantify
the relative contribution of single procedures.
Implications for research
The number of RCTs so far conducted on antibiotic prophylaxis
is substantial and provides suicient statistical power to detect
a moderate but humanly worthwhile eect of the treatment on
mortality. According to this systematic review, the combination of
topical and systemic antibiotics should be the standard against
which new treatments should be tested. A logical next step for
future trials would be the comparison of this protocol against a
regimen based on a systemic antimicrobial only; only six trials
included in this review chose this as their study design. However, it
is unlikely that one or more even large conventional trial can satisfy
the concerns of those who are afraid that antimicrobial resistance
may occur as a consequence of widespread use of antibiotics.
However, the trial by de Jonge (de Jonge 2003) has shown that trials
with innovative designs are possible and that they allow for a more
reliable assessment of the occurrence of antibiotic resistance.
At the current stage of development of this intervention there does
not seem to be a commercial interest by pharmaceutical companies
to support further trials. Similarly, the intensivists' community
seems rather sceptical about the merits of the intervention and it
is not willing to embark on new, properly designed and conducted
studies.
A systematic analysis of the quality and reliability of existing data
on resistance might, in this sense, be important to get a more
comprehensive view of the yield of the treatment. Such a review
should be carried out even though it is highly likely that the
necessary harms data are not available in published trials.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Randomised controlled study 
Blinding: Open 
Randomisation method: list block randomised assignments maintained by the main investigator 
Accrual period: not available
Participants Eligibility criteria: intubation within 24 hrs of admission, expected ventilation for at least four days, first
microbial culture within 36 hrs of admission 
Exclusion criteria: transfer from other hospitals, evidence of infection, prior antibiotic therapy, ARDS,
leucopenia, myelosuppression 
Patients enrolled in the study: 125; 37 patients were excluded leaving 88 patients for analysis 
Percentage of ventilated patients: 100% 
ICU length of stay, mean: 19.3 days 
Type of admission diagnosis: surgical unscheduled = 16% trauma = 84% 
Severity score on admission: APACHE II mean = 17, ISS not available 
Percentage of immunocompromised patients:not available 
Percentage of patients treated with systemic antibiotic therapy (not stated by protocol) in the first
three days: not available 
Stress ulcer prophylaxis applied: sucralfate 1 g x four to all patients
Interventions Group A, Treatment: 
- polymyxin 100 mg, tobramycin 80 mg, amphotericin B 500 mg applied orally four times a day as a 2%
paste during the ICU stay 
- cefotaxime 2 g x 3 iv x three days
Group B, CTR: 
- No prophylaxis
Antibiotic prophylaxis was performed only for abdominal, orthopedic and neurologic surgery
Outcomes Respiratory infections (acquired pneumonia): 
Abele-Horn 1997 
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Diagnosis was based on Clinical Pulmonary Infection Score as defined by Pugin 1991: new pulmonary
infiltrate on X-ray, increasing amount of tracheal secretions containing > 3 x 104 granulocytes/mcl and
at least two of the following: temperature > 38.5°C, WBC > 12,000/mm3 or < 4,000/mm3, decrease in
PaO2 requiring an increase in FiO2. Besides a bacteriological confirmation is required: tracheal aspi-
rates yielding bacteria > 104 CFU/ml and granulocytes > 10/field
Mortality: in ICU
Notes Data about 37 excluded patients are not available
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised study with three arms (one treatment arm versus two control arms) 
Blinding: outcome assessor 
Randomisation method: sealed envelopes, permuted block method. 
Accrual period: May 86 to Sept 87
Participants Eligibility criteria: expected ventilation for at least five days, inclusion within 24 hrs of admission 
Exclusion criteria: age < 16 yrs, pregnancy, allergy to one of the component of the regimen 
Patients enrolled in the study: 88 
Percentage of ventilated patients: 100% 
ICU length of stay, median: 16 days 
Type of admission diagnosis: medical = 40% surgical scheduled = 6% surgical unscheduled = 20% trau-
ma = 34% 
Severity score on admission: APACHE II mean = 21.8, ISS not available 
Percentage of immunocompromised patients: 4.6% 
Percentage of patients treated with systemic antibiotic therapy (not stated by protocol) in the first
three days: Treatment = 35% CTR = 80% 
Stress ulcer prophylaxis applied: antiacids until enteral feeding was possible
Interventions Group A, CTR 1: 
- No prophylaxis, infections of unknown origin were treated with ampicillin+gentamicin 
Group B, CTR 2: 
- No prophylaxis, infections of unknown origin were treated with cefotaxime+gentamicin and metron-
idazole if indicated. 
Group C, Treatment: 
- polymyxin E 200 mg, norfloxacin 50 mg, amphotericin B 500 mg applied enterally four times a day
and, as a 2% paste, to the oropharynx until extubation 
- cefotaxime 500 mg x 3 iv x five days. Infections of unknown origin were treated as group B
Outcomes Respiratory infections (acquired pneumonia and tracheobronchitis): 
Diagnosis of tracheobronchitis was based on: positive culture of the tracheal aspirate and a gram stain
showing many leukocytes as well as the causative organism, associated with two of the following: tem-
perature > 38°C, WBC > 12000/mm3, purulent tracheal aspirate 
Diagnosis of pneumonia was based on: a new and persistent pulmonary infiltrate on X-ray and criteria
of tracheobronchitis
Mortality: in ICU
Notes The study presents two control groups that are considered as a whole in the meta-analysis 
Aerdts 1991 
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Personal contact with the main investigator provided data about 32 patients who were excluded from
the published paper (16 early extubation, seven early deaths, five protocol violation, three other, one
unknown); these data are considered in the analysis
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised, placebo-controlled study. 
Blinding: double blind.
Participants Elegibility criteria: intubation within 24 hrs of admission and need for mechanical ventilation with an
expected duration > two hours 
Esclusion criteria: age < 16 yrs. 
Patients enrolled in the study: 226 
Percentage of ventilated patients: 100% 
ICU length of stay, median treatment group: 13 days; median control A group: 15 days, median control
B group: 12 days 
Type of admission diagnosis: Medical = 35%, Surgery = 39%, Trauma = 19%, Neurology = 6%, Other =
1%. 
Severity score on admission: APACHE II mean = 21.4, ISS not available 
Percentage of immuncompromised patients: 2% 
Percentage of patients treated with systematic antibiotic therapy at admission: 
Treatment: 47% CTR = 42% 
Stress ulcer prophylaxis applied: Treatment = 61% 
Control = 76%
Interventions Group A, Treatment: 
Orabase with 2% gentamicin, 2% colistin and 2% vancomycin 
Orabase was applied in the buccal cavities on a gloved finger every six hrs. 
The application of Orabase was started within 24 h of intubation. 
Application of treatment was limited to 21 days.
Group B, CTR1 
no prophylaxis 
- this group was studied in ICU in which there was the presence of patients receiving topical antimicro-
bial prophylaxis
Group C: CTR2 
no prophylaxis 
This control group was studied in ICU in which where no topical antimicrobial prophylaxis was used
Outcomes Ventilator-associated pneumonia (VAP); diagnosis of VAP was established on the basis of positive quan-
titative cultures from BAL (cutoff point >= 104 colony-forming units [cfu]/ml) or PSB (cutoff point >= 103
cfu/ml), or a positive blood culture unrelated to another source of infection, or a positive culture from
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Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised study 
Blinding: Open. 
Randomisation method: sealed envelopes. 
Accrual period: Sept. 1988 to Jan 1990
Participants Eligibility criteria: all admitted patients who do not fulfil the exclusion criteria 
Exclusion criteria: patients discharged within 48 hrs of ICU admission; admission from CCU; patients
expected to die after six hrs of ICU admission; patients with discharge anticipated within 48 hrs but re-
maining more than 48 hrs; drug overdose; security patients; age < 18 yrs; patients not randomised with-
in six hrs of admission; readmission to ICU; burns; miscellaneous
Patients enrolled in the study: 331 
Percentage of ventilated patients: 93% 
Length of stay in ICU, median: five days 
Type of admission diagnosis: medical = 14% surgical scheduled = 33% surgical unscheduled = 13%
trauma = 40% 
Severity score on admission: APACHE II mean = 14.4, ISS mean = 24.8 
Percentage of immunocompromised patients: 1.8% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 42% CTR = 74% 
Stress ulcer prophylaxis applied: all patients received ranitidine iv plus antiacid therapy if gastric pH
was low
Interventions Group A, CTR: 
- Standard antibiotic therapy (no prophylaxis)
Group B, Treatment: 
- polymyxin 100 mg, tobramycin 80 mg, amphotericin B 500 mg applied enterally four times a day and,
as a 2% gel, to the oropharynx 
- cefotaxime 50 mg/kg/day iv x four days
Outcomes Respiratory infections (pneumonia acquired after 48 hrs). Diagnosis of infection was based on the fulfil-
ment of Criteria I or Criteria II. 
Criteria I: temperature > 38.5°C on two separate occasion, WBC > 12 x 109/l or < 4 x 109 and a new pul-
monary infiltrate on X-ray. 
Criteria II: temperature > 37.5°C, a new pulmonary infiltrates on X-ray, purulent sputum and drop in
PaO2
Mortality: in ICU
Notes Personal contact with the main investigator provided data about 75 patients who were excluded from
the published paper for short length of stay; these data are considered in the analysis
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Low risk A - Adequate
Blair 1991 
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Methods Randomised, placebo-controlled study 
Blinding: double blind 
Randomisation method: computer generated randomisation directed by the pharmacy department 
Accrual period: Apr 89 to Mar 91
Participants Eligibility criteria: all multiple traumatised patients, intubated at the time of admission and likely to
stay intubated at least five days 
Exclusion criteria: patients who did not remain intubated for five days
Patients enrolled in the study: 64 
Percentage of ventilated patients: 100% 
Length of stay in ICU, median: eight days 
Type of admission diagnosis: trauma = 100% 
Severity score on admission: APACHE II mean = 16.8, ISS not available 
Percentage of immunocompromised patients: 0% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 0% CTR = 0% 
Stress ulcer prophylaxis applied: H2-blockers or sucralfate (78%)
Interventions Group A, CTR: 
- Placebo
Group B, Treatment: 
- polymyxin 100 mg, tobramycin 80 mg, nystatin 1,600,000 units applied enterally four times a day and,
as a 2% paste plus 60,000 units of nystatin, to the oropharynx until extubation or discharge 
- cefotaxime 1 g x 3 iv for the first three days
Outcomes Respiratory infections (acquired pneumonia and tracheobronchitis). 
Diagnosis of infection was based on: 
positive sputum culture for bacteria, fever > 38°C and leukocytosis (> 10,000 WBC/mm3 of blood)
Mortality: in ICU
Notes Personal contact with the main investigator provided data about 23 patients who were excluded from
the published paper (20 early extubations, three early deaths); these data are considered in the analy-
sis
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised trial 
Blinding: Open 
Randomisation method: odd and even birth year technique 
Accrual period: Apr 87 to May 87
Participants Eligibility criteria: patients with an admission SAPS > 2 and staying in the ICU more than 48 hrs 
Exclusion criteria: patients with severe neutropenia routinely receiving oral antibiotic prophylaxis 
Patients enrolled in the study: 133 
Percentage of ventilated patients: 59% 
Brun-Buisson 1989 
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Length of stay in ICU, median: 3.5 days 
Type of admission diagnosis: medical 75% surgical unscheduled 23% trauma 2% 
Severity score on admission: SAPS mean = 10.4, ISS not available 
Percentage of immunocompromised patients: 12.8% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 41% CTR = 53% 
Stress ulcer prophylaxis applied: none
Interventions Group A, Treatment: 
- polymyxin E 50 mg, neomycin 1 g, nalidixic acid 1 g, applied orally and enterally four times a day until
discharge 
- Oropharyngeal disinfectant in intubated patients
Group B, CTR: 
- Oropharyngeal disinfectant in intubated patients
Outcomes Respiratory infections (pneumonia acquired in the ICU or within 48 hrs from discharge) 
Diagnosis of infection was based on: 
purulent sputum or tracheal aspirate associated with a new and persistent pulmonary infiltrate on X-
ray and the culture of at least 109 CFU/l from a protected wedged catheter sample of bronchial aspi-
rate, temperature > 38°C, WBC > 10 x 109
Mortality: in ICU
Notes Setting: acute and intermediate areas of a medical ICU 
Personal contact with the main investigator provided data about 47 patients who were excluded from
the published paper (seven early deaths, one transferred, 39 other); these data are considered in the
analysis
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised trial 
Blinding: double 
Randomisation method: performed by computer 
Accrual period: April 1996 to October 1998
Participants Elegibility criteria: adults intubated for < 48 hrs and likely to require mechanical ventilation for > 48 hrs 
Exclusion criteria: patients with SAPS II > 80 and life expectancy of < 48 hrs resulting from brain death
of a palliative treatment, a polymorphonuclear count of < 500 cells/mm3, severe diarrhoea and anyone
who had received either a prior decontamination regimen or was already participating in another on-
going clinical trial. 
Patients enrolled: 256 
Pecentage of ventilated patients: not reported 
Length of stay in ICU: not reported 
Type of admission diagnosis: home/emergency department = 43%, hospital ward = 57% 
Severity score on admission: median SAPS II = 46 
Percentage of immunocompromised patients: 3.9% 
Percentage of patients treated with systemic antibiotic therapy (not stated in protocol) in the first three
days: none 
Stress ulcer prophylaxis applied: not reported
Camus 2005 
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Interventions Group A - Treatment: solution containing 15 mg/ml polymyxin E and 10 mg/ml tobramycin 
Group B - Control: placebo
Outcomes Respiratory infections: acquired infections 
Mortality: in ICU
Notes The study is a four arm, 2 x 2 factorial design. In this review we considered only two arms comparing
SDD regimen versus placebo
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised, placebo-controlled study 
Blinding: double blind 
Randomisation method: sealed envelopes 
Accrual period: Sept 1988 to Jan 1990
Participants Eligibility criteria: admission within 48 hrs from surgery, trauma or other acute event, expected stay at
least five days, hypermetabolism (VO2 > 140 ml/m2 or urinary nitrogen excretion > 10 g/day) without
progressive MOSF (normal transaminases, stable bilirubin and creatinine) 
Exclusion criteria: Cirrhosis, allergy to used drugs, chemo-radiotherapy, progressive MOSF, gastroin-
testinal leak or fistula
Patients enrolled in the study: 48 
Percentage of ventilated patients: not available 
ICU length of stay, median: not available 
Type of admission diagnosis: surgical = 96% trauma = 4% 
Severity score on admission: not available 
Percentage of immunocompromised patients: not available 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: not available 
Stress ulcer prophylaxis applied: not available
Interventions Group A, Treatment: 
- norfloxacin 500 mg x 3, nystatin one million U x 4 applied enterally until discharge
Group B, CTR: 
- Placebo
Outcomes Respiratory infections: not possible to evaluate
Mortality
Notes Personal contact with the main investigator provided data about two patients who were excluded from
the published paper for short length of stay); these data are considered in the analysis
Risk of bias
Bias Authors' judgement Support for judgement
Cerra 1992 
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Allocation concealment
(selection bias)




Methods Randomised study. Intention-to-treat 
Blinding: outcome assessor 
Randomisation method: randomisation table at a remote site in the pharmacy 
Accrual period: 1986 to 1989
Participants Eligibility criteria: all patients admitted to the mixed ICU if their condition suggested a prolonged stay
(> three days), age > 18 yrs 
Exclusion criteria: age < 18 yrs, pregnancy, allergy to one of the component of the regimen, infections,
antibiotic therapy 24 hrs before randomisation
Patients enrolled in the study: 150 
Percentage of ventilated patients: 85% 
ICU length of stay, median: 4.5 days 
Type of admission diagnosis: medical = 18% surgical scheduled = 27% surgical unscheduled = 21%
trauma = 34% 
Severity score on admission: APACHE II mean = 19.4, ISS mean 24.3 
Percentage of immunocompromised patients: 4% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 75% CTR = 80% 
Stress ulcer prophylaxis applied: H2-blockers (80%)
Interventions Group A, CTR: 
- No prophylaxis
Group B, Treatment: 
- gentamycin 80 mg, polymyxin B 100 mg, nystatin 2,000,000 units, applied enterally and as a 2% paste
to the oropharynx four times a day during the ICU stay 
- cefotaxime 1 g/8 hrs iv for the first three days
Outcomes Respiratory infections (only acquired infections) 
Diagnosis of pneumonia was based on clinical and laboratory criteria: 
a new or progressive pulmonary infiltrate, purulent secretions, isolation of a potential pathogen and
fever with or without leukocytosis. 
Diagnosis of tracheobronchitis was based on: 
the presence of increased purulent endotracheal secretions requiring frequent suctioning and the pres-




Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
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Methods Randomised study 
Blinding: Open 
Randomisation method:computer-generated random-number codes kept in sealed envelopes
Participants Eligibility criteria: adult patients admitted to ICU: with an expected stay of at least 72 hours and an ex-
pected duration of mechanical ventilation of at least 48 hours 
Exclusion criteria: 
previous admission in ICU within three months iper sensitivity to study medication, pregnancy and per-
ceived imminent death
Number of patients enrolled in the study: 934
Percentage of ventilated patients: 85%
Length of stay in ICU: median SDD group = 6.8 days 
control group = 8.5 days
Type of admission diagnosis: 
medical: 41% 
surgical urgent: 25% 
surgical elective: 34%
Severity score at admission: 
APACHE II mean = 18.7 
SAPS II in SDD group mean = 17.9 
SAPSII in control group mean = 17.1
Percentage of immunocompromised patients 
SDD group = 2.4% 
control group = 1.7%
Information on prescribed antibiotics per 1,000 patients available in the main publication
No stress ulcer prophylaxis by protocol
Interventions SDD group: topical plus systemic treatment 
Topical: oral paste containing 2% polymyxin E, 2% tobramycin, 2% amphotericin 
500 mg amphotericin B through gastric tubes 
Systemic: cefotaxime 1000 mg four times daily for four days
Control group: 
No antibiotic prophylaxis; antibiotic treatment based on clinical needs
Outcomes Colonisation, antibiotic resistance 
Mortality: in ICU and hospital
Notes Patients were allocated to either an SDD or a control unit to prevent cross-colonisation between SDD
and ICU control patients. Standard care was the same in the two units
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised, placebo-controlled study 
Ferrer 1994 
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Blinding: double blind 
Randomisation method: computer generated table 
Accrual period: Jan 91 to Mar 92
Participants Eligibility criteria: all mechanically ventilated patients expected to remain intubated for more than
three days 
Exclusion criteria: patients with HIV-related diseases or treated with antineoplastic chemotherapy as
well as patients who received transplants, extubation or death within 72 hrs
Number of patients enrolled in the study: 101 
Percentage of ventilated patients:100% 
Length of stay in ICU, median: 7.5 days 
Type of admission diagnosis: medical 66% surgical scheduled 6.9% surgical unscheduled 6.9% trauma
= 19.8% 
Severity score admission: SAPS mean = 12.1, ISS not available 
Percentage of immunocompromised patients: 0% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: not available 
treatment = 73% CTR = 74% 
Stress ulcer prophylaxis applied: sucralfate except in patients with paralytic ileus or with upper gas-
trointestinal bleeding, who were treated with ranitidine
Interventions Group A, Treatment: 
- polymyxin E 100 mg, tobramycin 80 mg, amphotericin B 500 mg applied enterally and, as a 2% paste,
to the oropharynx four times a day until extubation or death 
- cefotaxime 2 g/day iv for the first four days or others if required
Group B, CTR: 
- Placebo 
- cefotaxime 2 g/day iv for the first four days or others if required*
*patients infected on admission received adequate antibiotic treatment instead of cefotaxime
Outcomes Respiratory infections (pneumonia acquired after four days of mechanical ventilation) 
Diagnosis of infection was based on clinical criteria plus brush or BAL confirmation. 
Clinical criteria: new or progressive pulmonary X-ray infiltrate for at least 48 hrs, purulent tracheal se-
cretions, temperature > 38.5 °C and leukocytosis >= 12 x 109 WBC/l or leukopenia <= 4 x 109
Mortality: in ICU
Notes Personal contact with the main investigator provided data about 21 patients who were excluded from
the published paper (14 early extubations, six early deaths, one transfer); these data are considered in
the analysis
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised study 
Blinding: Open 
Randomisation method: sealed envelopes. Randomisation series made available to the hospital Phar-
macy only 
Finch 1991 
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Accrual period: Aug 87 to Sept 89
Participants Eligibility criteria: all patients whose length of stay was > 60 hrs, age > 16 yrs 
Exclusion criteria: none
Number of patients enrolled in the study: 49 
Percentage of ventilated patients: not available 
Length of stay in ICU: not available 
Type of admission diagnosis: medical 59% surgical scheduled 27% surgical unscheduled 10% trauma =
4% 
Severity score on admission: SAPS mean = 10.5, ISS not available 
Percentage of immunocompromised patients: 22% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 58% CTR = 68% 
Stress ulcer prophylaxis applied: not available
Interventions Group A, Treatment: 
- polymyxin B 100 mg, gentamycin 120 mg, amphotericin B 500 mg applied enterally and, as a 2%
paste, to the oropharynx four times a day 
- cefotaxime 1 g x 3 iv for the first four days
Group B, CTR: 
- Conventional antibiotic therapy
Outcomes Respiratory infections (acquired pneumonia) 
Diagnosis of pneumonia was based on: 
tracheal aspirate with numerous leukocytes associated with any of the following: a single bacterial
species with a growth density > 105 CFU, diagnosis of septicaemia, clinical signs of pulmonary infec-
tions (fever, leukocytosis and appropriate radiological findings)
Mortality: in ICU
Notes Personal contact with the main investigator provided information about mortality on five patients who
were excluded from the published paper (one early extubation, two early deaths, one transferring, one
unknown); these data are considered in the analysis. Data about respiratory infections in patients ex-
cluded from published paper are not available
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised, placebo-controlled, multicenter (15 ICUs) study Intention to treat 
Blinding: double blind 
Randomisation method: a randomised list of consecutive treatment assignments, performed separate-
ly in each unit. 
Accrual period: Feb 90 to Jun 90
Participants Eligibility criteria: all patients > 15 yrs who required mechanical ventilation and with intubation per-
formed no more than 48 hrs before randomisation 
Exclusion criteria: patients with ventilation for less than 24 hrs, drug or alcohol overdose, neutropenia
(WBC < 500/mm3), SAPS > 24 or GCS < 4, chronic degenerative central nervous system disease or spinal
cord injury above level of C4, acute severe enteropathy, pregnancy, participation in another ongoing
Gastinne 1992 
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clinical trial, refusal of consent, patients with conditions in which survival was strongly related to status
on admission
Number of patients enrolled in the study: 445 
Percentage of ventilated patients: 100% 
Length of stay in ICU, median: 12 days 
Type of admission diagnosis: medical 72% surgical scheduled 3% surgical unscheduled 10% trauma =
15% 
Severity score on admission: SAPS mean = 13.5, ISS not available GCS mean = 11.7 
Percentage of immunocompromised patients: 18% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 89% CTR = 84% 
Stress ulcer prophylaxis applied: sucralfate (43% patients), H2-blockers (13% patients)
Interventions Group A, CTR: 
- Placebo
Group B, Treatment: 
- tobramycin 80 mg, polymyxin E 100 mg, amphotericin B 100 mg applied enterally and, as a 2% paste,
to the oropharynx four times a day throughout the period of ventilation
Outcomes Respiratory infections (pneumonia diagnosed within 48 hrs and acquired): 
Diagnosis of infection was based on: 
purulent tracheal aspirate, temperature > 38.5°C, peripheral leukocytosis (> 10,000 WBC/mm3 of blood)




Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised study. Intention to treat 
Blinding: Open 
Randomisation method: odd-even numbers 
Accrual period: Sept 88 to Sept 89
Participants Eligibility criteria: all patients admitted to the ICU, who required mechanical ventilation and inotropic
drugs for haemodynamic reasons 
Exclusion criteria: neutropenia
Patients enrolled in the study: 118 
Percentage of ventilated patients: 100% 
ICU length of stay: not available 
Type of admission diagnosis: medical = 83% surgical scheduled = 17% (all patients were infected on ad-
mission) 
Severity score on admission: SAPS mean = 17.5 
Percentage of immunocompromised patients: not available 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 100% CTR = 100% 
Gaussorgues 1991 
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Stress ulcer prophylaxis applied: sucralfate 4 g to all patients
Interventions Group A, Treatment: 
- polymyxin E 36 mg, gentamycin 80 mg, Vancomycin 50 mg, amphotericin B 500 mg applied enterally
four times a day until extubation 
- amphotericin B, Clorexidine applied orally four times a day 
- systemic antibiotic therapy
Group B, CTR: 
- amphotericin B, Clorexidine applied orally four times a day 
- systemic antibiotic therapy
Outcomes Respiratory infections: not possible to evaluate
Mortality: in ICU
Notes All patients were infected on admission 
Data about respiratory infections are not provided
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised, placebo-controlled study 
Blinding: open 
Randomisation method: sealed envelopes 
Accrual period: Jun 1990 to April 1992
Participants Eligibility criteria: Polytrauma, expected mechanical ventilation for at least four days, age > 18 years 
Exclusion criteria: Hypersensitivity to the used agents, protocol violation, obesity, ventilation < four
days, patients on mechanical ventilation two days before admission, severe maxillo-facial lesions
Patients enrolled in the study: 138, but only 64 patients were analysed 
Length of stay in ICU, mean: 33 days 
Percentage of ventilated patients: 100%. Length of ventilation, mean: 16 days 
Type of admission diagnosis: trauma 100% 
Severity score on admission: APACHE II mean = 15, ISS = 41 
Percentage of immunocompromised patients: 0% 
Percentage of patients treated with systemic antibiotic therapy in the first 3 days: almost 100% 
Stress ulcer prophylaxis: H2-blockers
Interventions Group A: 
Treatment: polymyxin E 75 mg, Netilmicin 150 mg, amphotericin B 400 mg applied enterally four times
a day and, as a 2% paste, to the oropharynx until extubation 
- Systemic antibiotic prophylaxis was free
Group B: CTR 
- Placebo 
- Systemic antibiotic prophylaxis was free
Outcomes Respiratory infections (acquired pneumonia) 
Diagnosis of infection was based on: 
Georges 1994 
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Fever > 38.5 °C, leukocytosis > 12000/mm3, new infiltrates in the chest X-rays, purulent pulmonary se-
cretions, positive bacteriologic findings (> 10^3 CFU/ml) obtained through a protected catheter
Mortality: in ICU and hospital
Notes Antibiotic prophylaxis was free and almost all patients of both groups were treated with systemic an-
tibiotics 
74 potentially eligible patients were excluded from analysis; it is not evident if this happened before or
after randomisation; these data are not available
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised, placebo-controlled study 
Blinding: double blind 
Randomisation method: computer generated random numbers. 
Accrual period: Jan 89 to Dec 90
Participants Eligibility criteria: expected intubation for longer than 48 hrs and stay in ICU for at least five days 
Exclusion criteria: hypersensitivity to the study drugs, patients with asthma, drug overdose and pa-
tients admitted electively after surgery
Number of patients enrolled in the study: 322 
Percentage of ventilated patients: 100% 
Length of stay in ICU, median: 11 days 
Type of admission diagnosis: medical 55% surgical scheduled 3% surgical unscheduled 11% trauma =
31% 
Severity score on admission: APACHE II mean = 13.9, ISS mean = 28.7 
Percentage of immunocompromised patients: 0.8% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 54% CTR = 58% 
Stress ulcer prophylaxis applied: none, H2-blockers only to high risk patients
Interventions Group A, Treatment: 
- polymyxin E 100 mg, tobramycin 80 mg, amphotericin B 500 mg applied enterally and, as a 2% gel, to
the oropharynx four times a day until 48 hrs after extubation 
- cefotaxime 1 g x 3 iv for the first three days to patients untreated on admission
Group B, CTR: 
- Placebo 
- cefotaxime 1 g x 3 iv for the first three days to patients untreated on admission
Outcomes Respiratory infections (infections acquired after 48 hrs) 
Diagnosis of pneumonia was based on: 
a new infiltrate on X-ray and purulent bronchial secretions with many leukocytes, temperature > 38°C,
WBC > 1010/l, substantial number of organism on gram stain with a pure growth culture from tracheal
aspirate, deterioration of gas exchange of > 2 kPa 
Diagnosis of bronchial infection was based on: 
all the previous criteria except the X-ray changes
Mortality: in hospital
Hammond 1992 
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Notes Personal contact with the main investigator provided data on 82 patients who were excluded and sep-
arately considered in the published paper (78 short stay, three protocol violation, one unknown); these
data are considered in the analysis
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised study 
Blinding: open 
Randomisation method: sealed envelopes. 
Accrual period: Jul 89 to Aug 90
Participants Eligibility criteria: expected stay in ICU > three days 
Exclusion criteria: none
Patients enrolled in the study: 91 
Percentage of ventilated patients: 100% 
ICU length of stay, median: unknown 
Type of admission diagnosis: medical = 25% surgical = 57% trauma = 18% (high percentage of neuro-
logic and neurosurgical patients 52%) 
Severity score on admission: APACHE II mean = 17.5, ISS not available 
Percentage of immunocompromised patients: unknown 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: next to 100% 
Stress ulcer prophylaxis applied: policy of maintenance a low gastric pH, H2-blockers only if peptic ul-
cer or steroid therapy (33%), sucralfate 4 g to all patients not on enteral feeding
Interventions Group A, Treatment: 
- polymyxin E 100 mg, tobramycin 80 mg, amphotericin B 500 mg applied orally and enterally four
times a day until extubation 
- cefotaxime 50 mg/kg/day iv x four days
Group B, CTR: 
- No prophylaxis
Outcomes Respiratory infections (acquired pneumonia) 
Diagnosis of infection was based on: 
alveolar infiltrates on two or more chest X-rays, moderate or copious purulent tracheal aspirate, rec-
tal temperature > 38.4°C, leucocytosis > 13 x 109/l, a heavy growth of organisms from tracheal aspirate
with a high polymorphonuclear leucocytes/epithelial cell ratio
Mortality
Notes Almost 100% of patients received systemic antibiotic therapy on admission 
Personal contact with the main investigator provided data about 12 patients who were excluded from
the published paper (11 short stay in ICU, one HIV+); these data are considered in the analysis
Risk of bias
Bias Authors' judgement Support for judgement
Jacobs 1992 
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Allocation concealment
(selection bias)




Methods Randomised study 
Blinding: open 
Randomisation method: odd/even numbers 
Accrual period: Jan 85 to May 86
Participants Eligibility criteria: all patients admitted to the surgical ICU who required care > five days 
Exclusion criteria: none
Patients enrolled in the study: 96 
Percentage of ventilated patients: 100% 
ICU length of stay, not available 
Type of admission diagnosis: surgical = 60% trauma = 28% other = 12% 
Severity score on admission: APACHE II mean = 14.8, ISS not available 
Percentage of immunocompromised patients: not available 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: about 85% 
Stress ulcer prophylaxis applied: not available
Interventions Group A, Treatment: 
- polymyxin E 200 mg, tobramycin 80 mg, amphotericin B 500 mg applied orally and enterally four
times a day 
- Oral disinfectant 
- cefotaxime 50 to 70 mg/kg/day iv x five to seven days
Group B, CTR: 
- Oral disinfectant
Outcomes Respiratory infections (primary pneumonia and pneumonia acquired after 48hs) 
Diagnosis of infection was based on X-ray findings and the presence of three of the following criteria on
the same day: rectal temperature > 38.5°C for at least 12 hrs, WBC count > 10 x 103 or < 4 x 103/mcl, at
least 3% band forming granulocytes, unexplained decrease in platelet count < 100,000/mcl, deteriora-
tion of renal function due to acute tubular necrosis, unexplained decrease in systolic blood pressure of




Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised, placebo-controlled, dual-centre study 
Blinding: double blind 
Randomisation method: randomisation performed by the hospital pharmacist on each unit separately 
Korinek 1993 
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Accrual period: Mar 89 to Sep 90
Participants Eligibility criteria: all comatosed patients with emergency admission to two neurosurgical ICUs and in-
tubated within 24 hrs for at least five days, age > 16 yrs 
Exclusion criteria: age < 16 yrs, known immunosuppression, antibiotic treatment during the two weeks
preceding ICU admission, serious injury of oropharyngeal mucosa or epistaxis, abnormal chest X-ray on
admission, extubation or infection occurring within the first five days of neurosurgical care
Number of patients enrolled in the study: 191 
Percentage of ventilated patients: 100% 
Length of stay in ICU, mean: 26 days 
Type of admission diagnosis: surgical scheduled 11% surgical unscheduled 39% trauma 50% 
Severity score on admission: SAPS mean = 10.9, ISS not available 
Percentage of immunocompromised patients: 0% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 0% CTR = 0% 
Stress ulcer prophylaxis applied: sucralfate (32%), antiacids (14%), H2-blockers (20%) until enteral
feeding was started
Interventions Group A, Treatment: 
- polymyxin E 100 mg, tobramycin 80 mg, amphotericin B 500 mg applied enterally and, as a 2% paste,
to the oropharynx four times a day for 15 days 
- Vancomicin x os
Group B, CTR: 
- Placebo
The non-absorbable antibiotics were discontinued if any infection requiring a parenteral antibiotic
treatment occurred and at the time of patient's extubation
Outcomes Respiratory infections (pneumonia acquired after five days) 
Diagnosis of infection was based on: 
fever > 38.5°C, leukocytosis > 12,000 cells/mm3, purulent sputum, new and persistent infiltrates on
chest X-ray and a culture of > 103 CFU/ml obtained with either brush or plugged telescoping catheter
Mortality: in ICU
Notes Setting: neurosurgical ICU 
Personal contact with the main investigator provided data about 68 patients who were excluded from
the published paper (early extubation, early death, protocol violation, transferring, other); these data
are considered in the analysis
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised, double blind, placebo-controlled, double centre study 
Randomisation method: computer-generated randomisation 
Accrual period: Apr 89 to Mar 91
Participants Eligibility criteria: expected stay in ICU > two days and at least one risk factor for infection 
Exclusion criteria: patients expected to die within 48 hrs or randomisation was not achieved within 12
hrs after admission to ICU. 
Krueger 2002 
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Patients enrolled in the study: 546, 19 patients were excluded leaving 527 patients for analysis 
Percentage of ventilated patients: not available 
ICU length of stay: 10 days for both groups 
Type of admission diagnosis: surgical 
Severity score on admission: APACHE II mean = 20, ISS not available 
Percentage of immunocompromised patients: not available 
Percentage of patients treated with systemic antibiotic therapy (not stated by protocol) in the first
three days: not available 
Stress ulcer prophylaxis applied: sucralfate to all patients
Interventions Group A, Treatment: 
- polymyxin B 50 mg, gentamycin 80 mg, applied nasally, orally and enterally four times a day during
the ICU stay 
- ciprofloxacin 400 mg x 2 iv x four days to uninfected patients
Group B, CTR: 
- Placebo applied nasally, orally and enterally 
- Placebo iv to uninfected patients
Outcomes Respiratory infections (acquired pneumonia)
Mortality in ICU
Notes Information about accrual period and severity score was reported on an abstract previously published
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised, placebo-controlled study 
Blinding: double blind 
Randomisation method: computer generated randomisation in time blocks. Open 
Accrual period: Aug 87 to Nov 90
Participants Eligibility criteria: expected ventilation for five days, age > 18 yrs and < 80 yrs, acute onset of respiratory
failure 
Exclusion criteria: age < 18 yrs and > 80 yrs, bleeding of the nasopharynx and of the upper gastrointesti-
nal tract on admission, stress ulcer prophylaxis with other drug therapy than sucralfate, mechanical
ventilation for less than five days, patients on enteral nutrition or with known allergy to sucralfate or
gentamicin
Number of patients enrolled in the study: 88, but only 67 patients were analysed 
Percentage of ventilated patients: 100% 
Length of stay in ICU, mean: 28.8 days 
Type of admission diagnosis: medical 88% surgical scheduled 9% surgical unscheduled 1% trauma =
2% 
Severity score on admission: APACHE II mean = 23, ISS not available 
Percentage of immunocompromised patients: 15% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: 100% 
Stress ulcer prophylaxis applied: sucralfate
Interventions Group A, Treatment: 
Laggner 1994 
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- gentamycin 40 mg, amphotericin B 100 mg applied to the oropharynx four times a day until extuba-
tion 
- Oropharyngeal disinfectant 
- aminopenicillin and clavulanic acid or other appropriate regimens
Group B, CTR: 
- Placebo 
- Amphotericin B 100 mg 
- Oropharyngeal disinfectant 
- Aminopenicillin and clavulanic acid or other appropriate regimens
Outcomes Respiratory infections (acquired pneumonia): 
Diagnosis of infection was based on: 
appearance of a new infiltrate on the chest film with concomitant tracheal colonisation, fever > 38°C
and > 15,000 or < 5,000 WBC/mm3 of blood
Mortality: in ICU
Notes Data about 21 patients who were excluded from the published paper (18 short mechanical ventilation,
three early enteral nutrition) are not available
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised, placebo-controlled study with three arms (one control arm and two treatment arms). In-
tention to treat 
Blinding: double blind 
Randomisation method: continuous random numbers assigned to blinded study drugs or vehicle by
Biometric department. 
Accrual period: Aug 89 to Jan 94
Participants Eligibility criteria: non infected trauma patients, age > 18 yrs, expected ventilation for at least two days,
expected ICU stay for at least three days, ISS > 16 and < 74, inclusion within 24 hrs of admission 
Exclusion criteria: isolated brain injury, prior antibiotic treatment, history of infection
Patients enrolled in the study: 357 Percentage of ventilated patients: 100% 
ICU length of stay, mean: 20 days 
Type of admission diagnosis: trauma = 100% 
Severity score on admission: APACHE II mean = 15.6, ISS mean = 35.2 
Percentage of immunocompromised patients: 0% 
Percentage of patients treated with systemic antibiotic therapy (not stated by protocol) in the first
three days: treatment 1 = 2% treatment 2 = 2% CTR = 6% 
Stress ulcer prophylaxis applied: free
Interventions Group A, Treatment 1: 
- polymyxin E 100 mg, tobramycin 80 mg, amphotericin B 500 mg applied orally and enterally four
times a day during the ICU stay 
- ciprofloxacin 200 mg x 2 iv, for four days
Group C, CTR: 
- Placebo 
Lingnau 1997 
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- ciprofloxacin 200 mg x 2 iv, for four days
Outcomes Respiratory infections (acquired pneumonia): 
Diagnosis of infection was based on: 
concomitant occurrence of purulent sputum, positive cultures of bronchial secretions and deteriora-
tion of lung function
Mortality: in ICU
Notes This three arm study has been split in two comparisons; the control group C has been used twice: 
comparison Lingnau a (group A versus group C) 
comparison Lingnau b (group B versus group C)
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods see Lingnau 1997
Participants see Lingnau 1997 
Only two groups of patients, group B and C, are considered in this comparison, totaling 267 patients
Interventions Group B, Treatment 2: 
- polymyxin E 100 mg, ciprofloxacin 50 mg, amphotericin B 500 mg applied orally and enterally four
times a day during the ICU stay 
- ciprofloxacin 200 mg x 2 iv, for four days
Group C, CTR: 
- Placebo 
- ciprofloxacin 200 mg x 2 iv, for four days
Outcomes see Lingnau 1997
Notes see Lingnau 1997
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised, multicentric (10 ICUs) study with three arms (one treatment arm and two control arms;
one control arm was excluded from meta-analysis because it was the only one receiving sucralfate) 
Blinding: open 
Randomisation method: sealed envelopes. 
Accrual period: Jul 89 to Aug 91
Palomar 1997 
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Participants Eligibility criteria: patients requiring mechanical ventilation for more than four days, not infected at the
time of entry and not receiving antibiotic therapy 
Exclusion criteria: ARDS, leukopenia, pregnancy
Number of patients enrolled in the study: 97 
Percentage of ventilated patients: 100% 
Length of stay in ICU, median 10 days 
Type of admission diagnosis: medical 40% surgical 10% trauma 50% 
Severity score on admission: APACHE II mean = 16.8, ISS not available 
Percentage of immunocompromised patients: 0% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 0% CTR = 6% 
Stress ulcer prophylaxis applied: sucralfate to one control group (excluded from meta-analysis), an-
tiacids or H2-blockers to the two other groups
Interventions Group A, CTR 1: 
- No prophylaxis
Group B, Treatment: 
- polymyxin E + B 100 mg, tobramycin 80 mg, amphotericin B 500 mg applied enterally and, as a 2%
paste, to the oropharynx four times a day until extubation 
- cefotaxime 1 g x 3 iv for the first four days
Group C*, CTR 2: 
- cefotaxime 1 g x 3 iv for the first four days 
- sucralfate
* This group was excluded from analysis because it was the only one receiving sucralfate
Outcomes Respiratory infections (acquired infections) 
Diagnosis of pneumonia was based on the CDC criteria of 1980 (clinical or radiologic suspicion with:
purulent sputum, organism isolated from blood culture, isolation of pathogen from tracheal aspirate,
brush or biopsy. Bacteriologic evaluation was performed with brush or BAL in 50% of patients) 
Diagnosis of tracheobronchitis was based on the CDC criteria of 1980
Mortality: in ICU
Notes Personal contact with the main investigator provided data about 16 patients who were excluded from
the published paper (seven early extubations, five early deaths, three protocol violation, one other);
these data are considered in the analysis
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised, placebo-controlled 
Blinding: outcome assessor 
Randomisation method: not stated
Participants Elegibility criteria: patients with multiple trauma admitted to the intensive care unit who required intu-
bation and had an expected time for mechanical ventilation exceeding five days 
Absence of cardiopulmonary disease, negative chest radiography, and a PaO2/FIO2 ratio higher than
300 mmHg
Pneumatikos 2002 
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Patients enrolled in the study: 61
Percentage of ventilated patients: 100% 
ICU length of stay, median: 
Treatment = 16 days 
Control = 23 days 
Type of admission diagnosis: 
trauma = 100%
Severity score on admission: APACHE II 
treatment = 18.1 
control = 19.1 
Percentage of immunocompromised patients: not stated 
Percentage of patients treated with systemic antibiotic therapy: 
not stated 
Stress ulcer prophylaxis applied: H2 blockers or sucralfate 
Treatment = 26% 
Control = 19%
Interventions Group A, treatment: 
polymyxin 73 mg, 
tobramycin 73 mg, amphotericin 500 ml in 500 ml 0.9 saline solution at an infusion rate of 2 ml/hr in the
subglottic area for the entire period of the study
Group B CTR: 
placebo
Outcomes Ventilator associated pneumonia (VAP) defined as presence of new and persistent pulmonary infil-
trates in addition to two of the following criteria: body temperature > 38.3 °C, leukocytes/mm3) or
leukopenia (< 4000 leukocytes/mm3) and purulent tracheal secretions. The diagnosis of VAP was con-




Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised, placebo-controlled study 
Blinding: double blind 
Randomisation method: sealed envelopes 
Accrual period: Apr 89 to Nov 89
Participants Eligibility criteria: all adult patients admitted to the surgical ICU, at high risk of developing pneumonia
and intubated for more than 48 hrs 
Exclusion criteria: organ transplantation
Number of patients enrolled in the study: 79 
Percentage of ventilated patients: 100% 
Length of stay in ICU, mean 13.8 days 
Pugin 1991 
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Type of admission diagnosis: medical 11% surgical scheduled 11% surgical unscheduled 22% trauma
56% 
Severity score on admission: APACHE II mean = 15.2, ISS not available 
Percentage of immunocompromised patients: not available 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 46% CTR = 53% 
Stress ulcer prophylaxis applied: sucralfate (61%), ranitidine (11%)
Interventions Group A, Treatment: 
- polymyxin B sulfate 150 mg, neomycin sulfate 1 g, vancomycin hydrochloride 1 g applied as a solution
to the retropharynx six times a day within 24 hrs after intubation until extubation or death
Group B, CTR: 
- Placebo
Withdrawal from the study was possible at any time if the treating physicians estimated that there was
any problem related to administration of the drugs or side effects
Outcomes Respiratory infections (pneumonia acquired after 48 hrs): Pneumonia are defined by the "clinical pul-
monary infections score" (CPIS) greater or equal to seven during the course of intubation and that re-
mained elevated (=7) for at least three days (i.e. for two consecutive measurements)
Mortality: in hospital
Notes Personal contact with the main investigator provided data about 27 patients who were excluded from
the published paper (20 early extubations, seven early deaths); these data are considered in the analy-
sis
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised, placebo-controlled study. Intention to treat 
Blinding: double blind 
Randomisation method: randomisation made by the Pharmacy's Service according to computer gener-
ated random numbers. 
Accrual period: Jan 91 to Jan 93
Participants Eligibility criteria: trauma patients intubated within 24 hrs and ventilated for more than 48 hrs, ICU stay
> five days and decontamination for more than four days 
Exclusion criteria: age < 16 yrs, antibiotic treatment in the week precedent to ICU admission, pregnancy
Number of patients enrolled in the study: 149 
Percentage of ventilated patients: 100% 
Length of stay in ICU, mean = 20.5 days 
Type of admission diagnosis: medical 2% trauma 98% 
Severity score on admission: SAPS mean = 11.2, ISS mean = 31.3 
GCS mean 6.5 
Percentage of immunocompromised patients: 0% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 35% CTR = 26% 
Stress ulcer prophylaxis applied: sucralfate until enteral feeding was effective, H2-blockers in high risk
patients
Quinio 1995 
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Interventions Group A,Treatment: 
- polymyxin E 100 mg, gentamycin 80 mg, amphotericin B 500 mg applied enterally and in the nares
and, as a 2% paste, to the oropharynx four times a day until extubation or starting of enteral nutrition
Group B, CTR: 
- Placebo
Outcomes Respiratory infections (pneumonia acquired after 48 hrs): Diagnosis of infection was based on: 
purulent tracheal aspirate, fever > 38.5°C, leukocytosis > 10,000 WBC/mm3, new and persistent infil-




Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised, placebo-controlled study 
Blinding: double blind 
Randomisation method: made by the Pharmacy's service according to computer generated random
numbers 
Accrual period: Sept 89 to Oct 90
Participants Eligibility criteria: expected mechanical ventilation for more than three days, stay in ICU more than five
days 
Exclusion criteria: infection or strong suspicion of this at the start of ventilation, antibiotic treatment in
the previous seven days, neutropenia (WBC < 500/mm3) and fever, pregnancy, history of hypersensitivi-
ty to the topical agents
Number of patients enrolled in the study: 151 
Percentage of ventilated patients: 100% 
Length of stay in ICU, median eight days 
Type of admission diagnosis: medical 28% surgical scheduled 3% surgical unscheduled 1% trauma
68% 
Severity score on admission: APACHE II mean = 16.3, ISS not available, GCS mean = nine 
Percentage of immunocompromised patients: 0.7% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 0% CTR = 0% 
Stress ulcer prophylaxis applied: H2-blockers and antiacids
Interventions Group A, Treatment: 
- polymyxin E 100 mg, tobramycin 80 mg, amphotericin B 500 mg applied enterally and, as a 2% paste,
to the oropharynx four times a day 
- cefotaxime 6 g/day iv for the first four days
Group B, CTR: 
- Placebo 
- No systemic prophylaxis
Outcomes Respiratory infections (acquired pneumonia): 
Rocha 1992 
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Diagnosis of infection was based on: 
purulent pulmonary secretions, new infiltrates in the chest X-ray and one of the following: fever/hy-
pothermia, leukocytosis/leukopenia, positive physical examination, drop in arterial partial oxygen
pressure. Bacteriologic diagnosis, even if performed (with brush in few patients), was not essential
Mortality: in ICU
Notes Personal contact with the main investigator provided mortality data about 50 patients who were ex-
cluded from the published paper (15 early extubations, 31 early deaths, two protocol violation, two
other); these data are considered in the analysis. Data about respiratory infections in excluded patients
are not available
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised, placebo-controlled, dual-center study 
Blinding: double blind 
Randomisation method: odd and even numbers 
Accrual period: Jun 88 to Dec 88
Participants Eligibility criteria: patients intubated an mechanically ventilated for more than 72 hrs 
Exclusion criteria: patients whose chest X-rays was difficult to interpret, with suspected inflammatory
images during the first 72 hrs, patients ventilated for less time
Number of patients enrolled in the study: 31 
Percentage of ventilated patients: 100% 
Length of stay in ICU, median 13.5 days 
Type of admission diagnosis: medical 39% surgical scheduled 16% surgical unscheduled 3% trauma
42% 
Severity score on admission: APACHE II mean = 17.1, ISS not available 
Percentage of immunocompromised patients: 0% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 36% CTR = 35% 
Stress ulcer prophylaxis applied: sucralfate or alkaline agents plus ranitidine according to a ran-
domised open protocol
Interventions Group A, Treatment: 
- polymyxin E, Tobramicin or Netilmicin, amphotericin B and antiseptic applied enterally and, as a 2%
paste, to the oropharynx four times a day 
- Antiseptic
Group B, CTR: 
- Placebo 
- Antiseptic
Outcomes Respiratory infections (pneumonia acquired after 72 hrs): Diagnosis of infection was based on the pres-
ence of at least one in each category of criteria: 
A) Clinical criteria: temperature > 38°C, purulent bronchorrhoea, leukocytosis > 15,000 WBC/mm3, in-
creased alveolar-arterial oxygen gradient; 
B) Radiologic criteria: new and persistent infiltrate; 
C) Bacteriologic criteria: quantitative culture of tracheal aspirates > 103 CFU/ml (in six patients either
bronchoscopy or a telescoped catheter were used to obtain the sample)
Rodriguez-Rolda 1990 
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Mortality: in ICU
Notes Personal contact with the main investigator provided data about three patients who were excluded
from the published paper (two early deaths, one other); these data are considered in the analysis
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised, placebo-controlled, multicentric (five ICUs) study 
Blinding: double blind 
Randomisation method: sealed envelopes. 
Accrual period: not available
Participants Eligibility criteria: expected ventilation for longer than 48 hrs, age > 16 yrs 
Exclusion criteria: death or extubation before 48 hrs, pregnancy, allergy to study antibiotics, organ
transplantation, absence or contraindication to nasogastric tube
Number of patients enrolled in the study: 271 
Percentage of ventilated patients: 100% 
Length of stay in ICU, median 13 days 
Type of admission diagnosis: medical 70% surgical scheduled 3% surgical unscheduled 9% trauma
18% 
Severity score on admission: APACHE II mean = 26.6, ISS not available 
Percentage of immunocompromised patients: 4.4% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 70% CTR = 69% 
Stress ulcer prophylaxis applied: each group was randomised to receive either sucralfate or H2-block-
ers
Interventions Group A, Treatment: 
- polymyxin E 100 mg, gentamycin 80 mg, amphotericin B 500 mg applied orally and enterally four
times a day until extubation 
- Ceftriaxone 2 g/day iv x three days to uninfected patients
Group B, CTR: 
- Placebo 
- Systemic placebo to uninfected patients
Outcomes Respiratory infections (early and late acquired pneumonia): 
Diagnosis of infection was based on: 
new and persistent infiltrate on chest X-ray and three of the following: temperature > 38.5°C, leukocyto-
sis > 12,000 WBC/mm3 or leukopenia < 3,000 WBC/mm3, purulent tracheal aspirate with growth of a po-
tentially pathogenic micro-organism
Mortality: in ICU
Notes Personal contact with the main investigator provided data about 45 patients who were excluded from
the published paper (12 early extubations, 12 early deaths, 17 protocol violation, two transferring, two
other); these data are considered in the analysis
Risk of bias
Sanchez-Garcia 1992 
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Allocation concealment
(selection bias)




Methods Randomised, placebo-controlled study 
Blinding: double blind. 
Randomisation method: closed envelope method (the code was known by the pharmacist only). 
Accrual period: Nov 84 to Aug 86
Participants Eligibility criteria: all patients admitted to the surgical ICU with blunt trauma and an HTI-ISS > 18, age >
18 yrs 
Exclusion criteria: patients mechanically ventilated for less than five days or discharged from ICU with-
in seven days and with an HTI-ISS < 18 after 24 hrs
Number of patients enrolled in the study: 91 
Percentage of ventilated patients: 100% 
Length of stay in ICU, mean = 15 days 
Type of admission diagnosis: trauma 100% 
Severity score on admission: APACHE II mean = 10.6, HTI-ISS mean = 35.1 
Percentage of immunocompromised patients: 0% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 0% CTR = 0% 
Stress ulcer prophylaxis applied: none except for patients with history of preexisting ulcer or on H2-
blockers
Interventions Group A, Treatment: 
- polymyxin E 100 mg, tobramycin 80 mg, amphotericin 500 mg applied enterally and, as a 2% paste, to
the oropharynx four times a day until ICU discharge 
- cefotaxime 50 to 100 mg/kg/day iv for the first five days
Group B, CTR: 
- Placebo 
- cefotaxime 50 to 100 mg/kg/day iv for the first five days
The blinded medication was discontinued and topical prophylaxis was started when a patient devel-
oped MOSF not responding to conventional therapy. The code was not broken and the patient was fur-
ther evaluated
Outcomes Respiratory infections (tracheobronchitis and pneumonia - early and late infections) 
Diagnosis of infection was based on clinical criteria: temperature > 38.5°C, WBC > 12.5 x 109/l or
leukopenia < 4 x 10^9/l, purulent secretions or X-ray changes and significant growth of bacteria
Mortality: in ICU
Notes Data about 32 patients who were initially excluded (25 early extubations, four early deaths, three other)
are considered in the analysis
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Low risk A - Adequate
Stoutenbeek 1996 
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Methods Randomised, multicenter study. Intention to treat 
Blinding: open 
Randomisation method: randomisation lists prepared by the Biometrical Department and supplied
with sealed envelopes 
Accrual period: Oct 91 to Jun 94
Participants Eligibility criteria: patients admitted within 24 hrs after nonpenetrating blunt trauma with an HTI-ISS >=
16, necessitating mechanical ventilation, age > 18 yrs 
Exclusion criteria: previous antibiotic use for more than three days at study entry, allergy to cefotaxime,
referred patients from other hospital or secondary admissions with trauma occurred > 24 hrs before
Number of patients enrolled in the study: 405, but 401 patients were analysed 
Percentage of ventilated patients: 100% 
Median length of ICU stay: SDD = 13 days, CTR = 12 days 
Median duration of mechanical ventilation: SDD = nine days, CTR = eight days 
Type of admission diagnosis: trauma 100% 
Severity score on admission - APACHE II median: SDD = 15, CTR = 14 and HTI-ISS median: SDD = 34, CTR
= 29 
Percentage of immunocompromised patients: 0% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 46% CTR = 88% 
Stress ulcer prophylaxis applied: sucralfate, H2-blockers, omeprazole; no sucralfate
Interventions Group A, Treatment: 
- polymyxin E, tobramycin, amphotericin B administered through the nasogastric tube and applied to
the buccal mucosa four times a day until discharge 
- cefotaxime 1 g every six hours for four days
Group B, CTR: 
- Standard antibiotic prophylaxis used in each centres (no fluoroquinolones)
Outcomes Primary: Mortality from infection or multiple organ failure in ICU or up to two weeks after discharge
Secondary: incidence of infection, multiple organ failure and antibiotic usage
The maximum observation period was three months 
Patients dying within 24 hours after injury or dying from craniocerebral trauma were excluded
Diagnosis of pneumonia was based on any of the following: presence of a new and progressive pul-
monary infiltrate on chest X-ray for >= 48 hrs, purulent tracheal aspirate, fever > 38.5°C, leukocytosis >
12,000/ml or leukopenia < 4000/ml 
Diagnosis of tracheobronchitis was based on the same criteria except for the radiographic changes 
Mortality: in ICU or up to two weeks after discharge
Notes four patients were excluded from the final analysis after randomisation: two because they did not fulfil
the inclusion criteria, the data for one patient were not available and one was lost to follow-up after the
7th day
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
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Methods Randomised, placebo-controlled study 
Blinding: open 
Randomisation method: sealed envelopes containing a random code for clusters of four patients 
Accrual period: Oct 86 to Sep 87
Participants Eligibility criteria: patients expected to stay in the ICU more than five days and ventilated more than 48
hrs 
Exclusion criteria: patients who died within 24 hrs after randomisation
Number of patients enrolled in the study: 112 
Percentage of ventilated patients: about 80% 
Length of stay in ICU, median = 10 days 
Type of admission diagnosis: medical 34% surgical scheduled 19% surgical unscheduled 31% trauma
16% 
Severity score on admission: SAPS mean = 11.7, ISS mean = 36.9 
Percentage of immunocompromised patients: 3% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 83% CTR = 81% 
Stress ulcer prophylaxis applied: not available
Interventions Group A,Treatment: 
- polymyxin E 100 mg, norfloxacin 50 mg, amphotericin B 500 mg, applied enterally and, as a 2% paste,
to the oropharynx four times a day 
- Trimethoprim 500 mg iv
Group B, CTR: 
- Placebo
Outcomes Respiratory infections (acquired pneumonia): 
Diagnosis of infection was based on clinical and radiologic signs of pulmonary infiltrations with fever
and leukocytosis and a dense growth in cultures of sputum of tracheal aspirate
Mortality: in ICU
Notes Personal contact with the main investigator provided data about 12 patients who were excluded from
the published paper (early death); these data are considered in the analysis
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised study 
Blinding: outcome assessor 
Randomisation method: blocked randomisation scheme and the sealed envelope technique. Blind 
Accrual period: May 84 to Jan 85
Participants Eligibility criteria: all patients admitted to the ICU with: intubation within 24 hrs after the onset of an
acute disease or surgery, expected ventilation > six days, interval between intubation and first microbi-
ologic culture < 36 hrs 
Exclusion criteria: Patients with infection, systemic antibiotic treatment, respiratory distress syndrome,
leucopenia and myelosuppression on admission, renal failure
Unertl 1987 
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Number of patients enrolled in the study: 39 
Percentage of ventilated patients: 100% 
Length of stay in ICU: not available 
Type of admission diagnosis: medical 52%, surgical 15%, trauma 33% 
Severity score on admission: SAPS mean = 12.5, GCS (75% of patients have GCS < 7) 
Percentage of immunocompromised patients: not available 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: not available 
Stress ulcer prophylaxis applied: H2-blockers to all patients and antiacids if pH < 4
Interventions Group A, Treatment: 
- polymyxin B 50 mg, gentamycin 80 mg, applied orally, nasally and enterally four times a day until ex-
tubation 
- Amphoterycin B 300 mg applied orally four times a day
Group B, CTR: 
- No prophylaxis
Outcomes Respiratory infections (acquired pneumonia): 
Diagnosis of infection was based on: 
new 'definite' infiltrate on chest X-ray together with increasing amounts of purulent tracheobronchial
secretion containing > 3 x 104 granulocytes/mcl and at least two of the following: new febrile spikes >
38.5°C, blood leukocyte count > 12000/mcl or < 4000/mcl, decrease of PaO2 requiring an increase of the
FiO2 of at least 15% to maintain oxygen tension. 





Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised study with three arms (one control arm and two treatment arms) 
Blinding: open 
Randomisation method: sealed envelopes with computer generated random numbers 
Accrual period: Sept 89 to Mar 91
Participants Eligibility criteria: expected ventilation > 48 hrs 
Exclusion criteria: age < 18 yrs, pregnancy, recent organ transplantation, serious granulocytopenia (<=
500 WBC/mm3), ventilation < 48 hrs, death before 48 hrs, missing of essential data in the clinical or bac-
teriological dossier
Number of patients enrolled in the study: 660 (only two groups of patients, A and B, are considered in
this comparison, totaling 440 patients) 
Percentage of ventilated patients: 100% 
Length of stay in ICU, mean = 19.6 days 
Type of admission diagnosis: medical 10%, surgical 67% trauma 23% 
Severity score on admission: APACHE II mean = 18.1, ISS not available 
Percentage of immunocompromised patients: not available 
Verwaest 1997 
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Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment one = 34% treatment twp = 31% CTR = 34% 
Stress ulcer prophylaxis applied: sucralfate 2 g x 4
Interventions Group A, CTR: 
- No prophylaxis, antibiotic therapy was used only if an infection was suspected
Group B, Treatment 1: 
- Ofloxacin 200 mg x 2, Amphoterycin B 500 mg x 4 applied enterally and, as a 2% paste, to the orophar-
ynx four times a day until discharge 
- Ofloxacin 200 mg iv x four days
Outcomes Respiratory infections (pneumonia acquired after 48 hrs): 
Diagnosis of infection was based on: 
Fever > 38.5°C, leukocytosis > 10,000 cells/mcl, luxuriant growth of potentially pathogenic micro-organ-
isms in culture of bronchial aspirate, new and persistent infiltrate on chest X-ray
Mortality: in ICU
Notes Personal contact with the main investigator provided mortality data about 82 patients who were ex-
cluded (33 early deaths, 49 other); these data are considered in the analysis.Data about respiratory in-
fections in excluded patients are not available
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised, placebo-controlled study 
Blinding: double blind 
Randomisation method: random number table in blocks of six patients 
Accrual period: eight months
Participants Eligibility criteria: expected intubation for more than 48 hrs, inclusion within 18 hrs of intubation, age >
18 yrs 
Exclusion criteria: refusal to consent, allergy to one of the components of the regimen, active inflam-
matory bowel disease
Patients enrolled in the study: 121, but 60 patients were excluded leaving 61 patients for analysis 
Percentage of ventilated patients: 100% 
Length of stay in ICU, mean: 11.3 days 
Type of admission diagnosis: not available 
Severity score on admission: APACHE II mean = 27.2, ISS not available 
Percentage of immunocompromised patients: > 5% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 93% CTR = 81% 
Stress ulcer prophylaxis applied: H2-blockers to most patients
Interventions Group A, Treatment: 
- polymyxin E 100 mg, gentamycin 80 mg, nystatin 2,000,000 UI applied enterally four times a day and,
as a 2% paste, to the oropharynx until extubation or tracheostomy
Group B, CTR: 
Wiener 1995 
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- Placebo
Outcomes Respiratory infections (pneumonia acquired after 48 hrs): 
Diagnosis of infection was based on the presence of the following: persistence of a new or progressive
infiltrate on chest-film, fever > 38.5°C and/or leukocytosis > 12,000/mm3, growth of > 103 bacteria from
a quantitative culture of lower respiratory tract secretions obtained with a blind protected catheter
Mortality: in ICU
Notes 60 patients were excluded after randomisation; data are not available
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)




Methods Randomised study 
Blinding: open. 
Randomisation method: sealed envelopes based on a computer generated table of random numbers. 
Accrual period: Jul 88 to May 90
Participants Eligibility criteria: patients likely to remain in the ICU for at least 48 hrs 
Exclusion criteria: allergy to the antibiotics used, age > 85 yrs, pregnancy
Patients enrolled in the study: 183 
Percentage of ventilated patients: 92% 
Length of stay in ICU, median = four days 
Type of admission diagnosis: medical 40% surgical scheduled 10% surgical unscheduled 37% trauma
13% 
Severity score on admission: APACHE II mean = 15.3, ISS mean = 26.2 
Percentage of immunocompromised patients: 2.2% 
Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first
three days: treatment = 47% CTR = 64% 
Stress ulcer prophylaxis applied: all CTR patients received sucralfate; H2-blockers were used in patients
of both groups with peptic ulcer or pancreatitis
Interventions Group B, CTR: 
- Conventional infections treatment and prophylaxis
Group C, Treatment: 
- polymyxin E 100mg, tobramycin 80mg, amphotericin B 500 mg applied enterally and, as a 2% gel, to
the oropharynx four times a day 
- Ceftazidime 50mg/kg/day iv x three days
Outcomes Respiratory infections (pneumonia acquired after 48 hrs): Diagnosis of infection was based on: 
temperature > 38.5°C two times in 24 hrs, WBC < 4 or > 12 x 109/l, positive BAL, two of the following:
new pulmonary infiltrates on chest X-ray, purulent sputum, increase of 15% in FiO2 to maintain previ-
ous oxygenation
Mortality: in hospital
Notes Few patients were excluded after randomisation; data are not available
Winter 1992 
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Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Low risk A - Adequate
Winter 1992  (Continued)
APACHE Acute Physiology and Chronic Health Evaluation
ARDS Acute Respiratory Distress Syndrome
BAL Broncho-Alveolar-Lavage
CCU Coronary Care Unit
CDC Centre for Disease Control
CFU Colony Forming Unit
CI Confidence Interval
CTR Control group
GCS Glasgow Coma Score
hrs hours
HTI-ISS Hospital Trauma Index-Injury Severity Score
ICU Intensive Care Unit




RCTs Randomised Controlled Trials
RD Risk Dierences
RR Relative Risk
RTIs Respiratory Tract Infections
SAPS Symplified Acute Physiology Score
SDD Selective Decontamination of the Digestive Tract
VAP Ventilator Associated Pneumonia
VO2 Oxygen Consumption
yrs years
WBC White Blood Count
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Arnow 1996 The study included a selected population of patients undergoing liver transplant
Barret 2001 The study included only paediatric burns patients
Bion 1994 The study included a selected population of patients undergoing liver transplant
Bouter 2002 The study included only patients undergoing cardiopulmonary by-pass
de la Cal 2005 The study included only critically ill burns patients
de Smet 2009 The study adopted a cluster design with type of treatments alternated for specific periods of time
across participating hospitals. As a consequence patients were not properly randomised and the
study could be affected by selection bias.
Flaherty 1990 The study included a selected population of cardio surgical patients
Garbino 2002 The study tested the effectiveness of fluconazole as both groups received SDD
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Study Reason for exclusion
Hellinger 2002 The study included only liver transplant patients
Hunefeld 1989 After contacting the principal investigator it become apparent that it was not a randomised study
Jacobs 1995 This study, included in the previous version of this review as a personal contact with the principal
investigator, has been excluded due to lack of feedback from the trial author. To date, this study
has never been published
Lenhart 1994 This study, included in the previous version of this review as a congress proceeding, has been re-
placed by its published article (Krueger 2002)
Lipman 1994 After contacting the principal investigator it become apparent that it was not a randomised study
Luiten 1995 The study included a selected population of patients affected by pancreatitis characterised by a
low percentage of ICU admissions.
Martinez 1994 The study compared the effect of two different prophylactic regimens without a control group
Martinez-Pellus 1993 The study included a selected population of cardio surgical patients
Nardi 2001 The study tested the effectiveness of mupirocin as both groups received SDD
Rayes 2002 The study included only liver transplant patients
Rolando 1996 The study included a selected population of patients with acute hepatic failure
Ruza 1998 The study included only paediatric burns patients
Schardey 1997 The study included a selected population of patients undergoing gastric surgery and characterised
by a low percentage of ICU admission
Smith 1993 The study included only paediatric, liver transplant patients
Stoutenbeek 2 This unpublished study, included in the previous version of this review, has been replaced by its
published article (Stoutenbeek 2007)
Tetteroo 1990 The study included a selected population of patients undergoing oesophageal resection and char-
acterised by a short length of stay in ICU
Zobel 1991 The study included only paediatric patients
Zwaveling 2002 The study included only liver transplant patients
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Comparison 1.   Topical plus systemic versus no prophylaxis





Statistical method Effect size
1 Overall mortality 17 4075 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.65, 0.87]
2 Mortality according to quality of al-
location concealment
17 4075 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.65, 0.87]
2.1 Adequate 10 3336 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.66, 0.90]
2.2 Not adequate 7 739 Odds Ratio (M-H, Fixed, 95% CI) 0.67 [0.48, 0.93]
3 Mortality according to blinding of
the studies
17 4075 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.65, 0.87]
3.1 Double-blind 4 1013 Odds Ratio (M-H, Fixed, 95% CI) 0.63 [0.48, 0.83]
3.2 Open 13 3062 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.68, 0.95]
4 RTIs 16 3024 Odds Ratio (M-H, Random, 95% CI) 0.28 [0.20, 0.38]
5 RTIs according to quality of alloca-
tion concealment
16 3024 Odds Ratio (M-H, Random, 95% CI) 0.28 [0.20, 0.38]
5.1 Adequate 9 2335 Odds Ratio (M-H, Random, 95% CI) 0.36 [0.27, 0.47]
5.2 Not adequate 7 689 Odds Ratio (M-H, Random, 95% CI) 0.19 [0.10, 0.37]
6 RTIs according to blinding of the
studies
16 3024 Odds Ratio (M-H, Random, 95% CI) 0.28 [0.20, 0.38]
6.1 Double-blind 4 963 Odds Ratio (M-H, Random, 95% CI) 0.40 [0.30, 0.53]
6.2 Open 12 2061 Odds Ratio (M-H, Random, 95% CI) 0.22 [0.14, 0.34]
 
 
Analysis 1.1.   Comparison 1 Topical plus systemic versus no prophylaxis, Outcome 1 Overall mortality.
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Abele-Horn 1997 11/58 5/30 1.21% 1.17[0.37,3.74]
Aerdts 1991 4/28 12/60 1.48% 0.67[0.19,2.29]
Blair 1991 24/161 32/170 6% 0.76[0.42,1.35]
Boland 1991 2/32 4/32 0.85% 0.47[0.08,2.75]
Cockerill 1992 11/75 16/75 3.09% 0.63[0.27,1.48]
de Jonge 2003 113/466 146/468 24.99% 0.71[0.53,0.94]
Finch 1991 15/24 10/25 0.83% 2.5[0.79,7.9]
Jacobs 1992 14/45 23/46 3.55% 0.45[0.19,1.06]
Kerver 1988 14/49 15/47 2.48% 0.85[0.36,2.04]
Krueger 2002 52/265 75/262 13.73% 0.61[0.41,0.91]
Palomar 1997 14/50 14/49 2.31% 0.97[0.41,2.33]
Favours treatment 100.1 50.2 20.5 1 Favours control
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Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Rocha 1992 27/74 40/77 5.64% 0.53[0.28,1.02]
Sanchez-Garcia 1992 51/131 65/140 8.69% 0.74[0.45,1.19]
Stoutenbeek 2007 42/201 44/200 7.9% 0.94[0.58,1.51]
Ulrich 1989 22/55 33/57 4.4% 0.48[0.23,1.03]
Verwaest 1997 47/220 40/220 7.12% 1.22[0.76,1.96]
Winter 1992 33/91 40/92 5.74% 0.74[0.41,1.34]
   
Total (95% CI) 2025 2050 100% 0.75[0.65,0.87]
Total events: 496 (Treatment), 614 (Control)  
Heterogeneity: Tau2=0; Chi2=15.55, df=16(P=0.49); I2=0%  
Test for overall effect: Z=3.94(P<0.0001)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.2.   Comparison 1 Topical plus systemic versus no prophylaxis,
Outcome 2 Mortality according to quality of allocation concealment.
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.2.1 Adequate  
Aerdts 1991 4/28 12/60 1.48% 0.67[0.19,2.29]
Blair 1991 24/161 32/170 6% 0.76[0.42,1.35]
de Jonge 2003 113/466 146/468 24.99% 0.71[0.53,0.94]
Finch 1991 15/24 10/25 0.83% 2.5[0.79,7.9]
Sanchez-Garcia 1992 51/131 65/140 8.69% 0.74[0.45,1.19]
Stoutenbeek 2007 42/201 44/200 7.9% 0.94[0.58,1.51]
Ulrich 1989 22/55 33/57 4.4% 0.48[0.23,1.03]
Verwaest 1997 47/220 40/220 7.12% 1.22[0.76,1.96]
Winter 1992 33/91 40/92 5.74% 0.74[0.41,1.34]
Krueger 2002 52/265 75/262 13.73% 0.61[0.41,0.91]
Subtotal (95% CI) 1642 1694 80.88% 0.77[0.66,0.9]
Total events: 403 (Treatment), 497 (Control)  
Heterogeneity: Tau2=0; Chi2=11.58, df=9(P=0.24); I2=22.31%  
Test for overall effect: Z=3.23(P=0)  
   
1.2.2 Not adequate  
Abele-Horn 1997 11/58 5/30 1.21% 1.17[0.37,3.74]
Boland 1991 2/32 4/32 0.85% 0.47[0.08,2.75]
Cockerill 1992 11/75 16/75 3.09% 0.63[0.27,1.48]
Jacobs 1992 14/45 23/46 3.55% 0.45[0.19,1.06]
Kerver 1988 14/49 15/47 2.48% 0.85[0.36,2.04]
Palomar 1997 14/50 14/49 2.31% 0.97[0.41,2.33]
Rocha 1992 27/74 40/77 5.64% 0.53[0.28,1.02]
Subtotal (95% CI) 383 356 19.12% 0.67[0.48,0.93]
Total events: 93 (Treatment), 117 (Control)  
Heterogeneity: Tau2=0; Chi2=3.35, df=6(P=0.76); I2=0%  
Test for overall effect: Z=2.39(P=0.02)  
   
Total (95% CI) 2025 2050 100% 0.75[0.65,0.87]
Total events: 496 (Treatment), 614 (Control)  
Favours treatment 200.05 50.2 1 Favours control
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Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Heterogeneity: Tau2=0; Chi2=15.55, df=16(P=0.49); I2=0%  
Test for overall effect: Z=3.94(P<0.0001)  
Test for subgroup differences: Chi2=0.63, df=1 (P=0.43), I2=0%  
Favours treatment 200.05 50.2 1 Favours control
 
 
Analysis 1.3.   Comparison 1 Topical plus systemic versus no
prophylaxis, Outcome 3 Mortality according to blinding of the studies.
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.3.1 Double-blind  
Boland 1991 2/32 4/32 0.85% 0.47[0.08,2.75]
Krueger 2002 52/265 75/262 13.73% 0.61[0.41,0.91]
Rocha 1992 27/74 40/77 5.64% 0.53[0.28,1.02]
Sanchez-Garcia 1992 51/131 65/140 8.69% 0.74[0.45,1.19]
Subtotal (95% CI) 502 511 28.9% 0.63[0.48,0.83]
Total events: 132 (Treatment), 184 (Control)  
Heterogeneity: Tau2=0; Chi2=0.79, df=3(P=0.85); I2=0%  
Test for overall effect: Z=3.3(P=0)  
   
1.3.2 Open  
Abele-Horn 1997 11/58 5/30 1.21% 1.17[0.37,3.74]
Aerdts 1991 4/28 12/60 1.48% 0.67[0.19,2.29]
Blair 1991 24/161 32/170 6% 0.76[0.42,1.35]
Cockerill 1992 11/75 16/75 3.09% 0.63[0.27,1.48]
de Jonge 2003 113/466 146/468 24.99% 0.71[0.53,0.94]
Finch 1991 15/24 10/25 0.83% 2.5[0.79,7.9]
Jacobs 1992 14/45 23/46 3.55% 0.45[0.19,1.06]
Kerver 1988 14/49 15/47 2.48% 0.85[0.36,2.04]
Palomar 1997 14/50 14/49 2.31% 0.97[0.41,2.33]
Stoutenbeek 2007 42/201 44/200 7.9% 0.94[0.58,1.51]
Ulrich 1989 22/55 33/57 4.4% 0.48[0.23,1.03]
Verwaest 1997 47/220 40/220 7.12% 1.22[0.76,1.96]
Winter 1992 33/91 40/92 5.74% 0.74[0.41,1.34]
Subtotal (95% CI) 1523 1539 71.1% 0.8[0.68,0.95]
Total events: 364 (Treatment), 430 (Control)  
Heterogeneity: Tau2=0; Chi2=12.55, df=12(P=0.4); I2=4.36%  
Test for overall effect: Z=2.61(P=0.01)  
   
Total (95% CI) 2025 2050 100% 0.75[0.65,0.87]
Total events: 496 (Treatment), 614 (Control)  
Heterogeneity: Tau2=0; Chi2=15.55, df=16(P=0.49); I2=0%  
Test for overall effect: Z=3.94(P<0.0001)  
Test for subgroup differences: Chi2=2.24, df=1 (P=0.13), I2=55.36%  
Favours treatment 100.1 50.2 20.5 1 Favours control
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Analysis 1.4.   Comparison 1 Topical plus systemic versus no prophylaxis, Outcome 4 RTIs.
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Abele-Horn 1997 13/58 23/30 5.34% 0.09[0.03,0.25]
Aerdts 1991 1/28 29/60 1.94% 0.04[0.01,0.31]
Blair 1991 12/161 38/170 8.17% 0.28[0.14,0.56]
Boland 1991 14/32 17/32 5.75% 0.69[0.26,1.84]
Cockerill 1992 4/75 12/75 4.58% 0.3[0.09,0.96]
Finch 1991 4/20 7/24 3.58% 0.61[0.15,2.48]
Jacobs 1992 0/45 4/46 1.02% 0.1[0.01,1.99]
Kerver 1988 5/49 31/47 5% 0.06[0.02,0.18]
Palomar 1997 10/50 25/49 6.43% 0.24[0.1,0.59]
Rocha 1992 7/47 25/54 5.89% 0.2[0.08,0.53]
Sanchez-Garcia 1992 32/131 60/140 9.91% 0.43[0.26,0.73]
Stoutenbeek 2007 62/201 100/200 11.11% 0.45[0.3,0.67]
Ulrich 1989 7/55 26/57 6% 0.17[0.07,0.45]
Verwaest 1997 22/193 40/185 9.43% 0.47[0.26,0.82]
Winter 1992 3/91 17/92 4.17% 0.15[0.04,0.53]
Krueger 2002 91/265 149/262 11.69% 0.4[0.28,0.56]
   
Total (95% CI) 1501 1523 100% 0.28[0.2,0.38]
Total events: 287 (Treatment), 603 (Control)  
Heterogeneity: Tau2=0.18; Chi2=33.77, df=15(P=0); I2=55.58%  
Test for overall effect: Z=8.11(P<0.0001)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.5.   Comparison 1 Topical plus systemic versus no prophylaxis,
Outcome 5 RTIs according to quality of allocation concealment.
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.5.1 Adequate  
Aerdts 1991 1/28 29/60 1.94% 0.04[0.01,0.31]
Blair 1991 12/161 38/170 8.17% 0.28[0.14,0.56]
Finch 1991 4/20 7/24 3.58% 0.61[0.15,2.48]
Sanchez-Garcia 1992 32/131 60/140 9.91% 0.43[0.26,0.73]
Stoutenbeek 2007 62/201 100/200 11.11% 0.45[0.3,0.67]
Ulrich 1989 7/55 26/57 6% 0.17[0.07,0.45]
Verwaest 1997 22/193 40/185 9.43% 0.47[0.26,0.82]
Winter 1992 3/91 17/92 4.17% 0.15[0.04,0.53]
Krueger 2002 91/265 149/262 11.69% 0.4[0.28,0.56]
Subtotal (95% CI) 1145 1190 66.01% 0.36[0.27,0.47]
Total events: 234 (Treatment), 466 (Control)  
Heterogeneity: Tau2=0.05; Chi2=12.03, df=8(P=0.15); I2=33.49%  
Test for overall effect: Z=7.37(P<0.0001)  
   
1.5.2 Not adequate  
Abele-Horn 1997 13/58 23/30 5.34% 0.09[0.03,0.25]
Kerver 1988 5/49 31/47 5% 0.06[0.02,0.18]
Boland 1991 14/32 17/32 5.75% 0.69[0.26,1.84]
Cockerill 1992 4/75 12/75 4.58% 0.3[0.09,0.96]
Favours treatment 1000.01 100.1 1 Favours control
Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care (Review)









Cochrane Database of Systematic Reviews
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Rocha 1992 7/47 25/54 5.89% 0.2[0.08,0.53]
Jacobs 1992 0/45 4/46 1.02% 0.1[0.01,1.99]
Palomar 1997 10/50 25/49 6.43% 0.24[0.1,0.59]
Subtotal (95% CI) 356 333 33.99% 0.19[0.1,0.37]
Total events: 53 (Treatment), 137 (Control)  
Heterogeneity: Tau2=0.42; Chi2=13.9, df=6(P=0.03); I2=56.85%  
Test for overall effect: Z=4.99(P<0.0001)  
   
Total (95% CI) 1501 1523 100% 0.28[0.2,0.38]
Total events: 287 (Treatment), 603 (Control)  
Heterogeneity: Tau2=0.18; Chi2=33.77, df=15(P=0); I2=55.58%  
Test for overall effect: Z=8.11(P<0.0001)  
Test for subgroup differences: Chi2=3.11, df=1 (P=0.08), I2=67.81%  
Favours treatment 1000.01 100.1 1 Favours control
 
 
Analysis 1.6.   Comparison 1 Topical plus systemic versus no
prophylaxis, Outcome 6 RTIs according to blinding of the studies.
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.6.1 Double-blind  
Boland 1991 14/32 17/32 5.75% 0.69[0.26,1.84]
Rocha 1992 7/47 25/54 5.89% 0.2[0.08,0.53]
Sanchez-Garcia 1992 32/131 60/140 9.91% 0.43[0.26,0.73]
Krueger 2002 91/265 149/262 11.69% 0.4[0.28,0.56]
Subtotal (95% CI) 475 488 33.23% 0.4[0.3,0.53]
Total events: 144 (Treatment), 251 (Control)  
Heterogeneity: Tau2=0; Chi2=3.13, df=3(P=0.37); I2=4.29%  
Test for overall effect: Z=6.37(P<0.0001)  
   
1.6.2 Open  
Abele-Horn 1997 13/58 23/30 5.34% 0.09[0.03,0.25]
Aerdts 1991 1/28 29/60 1.94% 0.04[0.01,0.31]
Blair 1991 12/161 38/170 8.17% 0.28[0.14,0.56]
Cockerill 1992 4/75 12/75 4.58% 0.3[0.09,0.96]
Finch 1991 4/20 7/24 3.58% 0.61[0.15,2.48]
Jacobs 1992 0/45 4/46 1.02% 0.1[0.01,1.99]
Kerver 1988 5/49 31/47 5% 0.06[0.02,0.18]
Palomar 1997 10/50 25/49 6.43% 0.24[0.1,0.59]
Stoutenbeek 2007 62/201 100/200 11.11% 0.45[0.3,0.67]
Ulrich 1989 7/55 26/57 6% 0.17[0.07,0.45]
Verwaest 1997 22/193 40/185 9.43% 0.47[0.26,0.82]
Winter 1992 3/91 17/92 4.17% 0.15[0.04,0.53]
Subtotal (95% CI) 1026 1035 66.77% 0.22[0.14,0.34]
Total events: 143 (Treatment), 352 (Control)  
Heterogeneity: Tau2=0.3; Chi2=27.71, df=11(P=0); I2=60.3%  
Test for overall effect: Z=6.75(P<0.0001)  
   
Total (95% CI) 1501 1523 100% 0.28[0.2,0.38]
Favours treatment 1000.01 100.1 1 Favours control
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Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 287 (Treatment), 603 (Control)  
Heterogeneity: Tau2=0.18; Chi2=33.77, df=15(P=0); I2=55.58%  
Test for overall effect: Z=8.11(P<0.0001)  
Test for subgroup differences: Chi2=4.93, df=1 (P=0.03), I2=79.73%  
Favours treatment 1000.01 100.1 1 Favours control
 
 
Comparison 2.   Topical versus control





Statistical method Effect size
1 Overall mortality 20 3016 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.82, 1.16]
1.1 Topical plus systemic versus systemic 7 1233 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.73, 1.32]
1.2 Topical versus no prophylaxis 13 1783 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.79, 1.20]
2 Mortality according to quality of alloca-
tion concealment
20 3016 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.82, 1.16]
2.1 Adequate 2 139 Odds Ratio (M-H, Fixed, 95% CI) 0.64 [0.27, 1.52]
2.2 Not adequate 18 2877 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.83, 1.18]
3 Mortality according to blinding of the
studies
20 3016 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.82, 1.16]
3.1 Double-blind 15 2601 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.83, 1.20]
3.2 Open 5 415 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.56, 1.37]
4 RTIs 18 2850 Odds Ratio (M-H, Random, 95%
CI)
0.44 [0.31, 0.63]
4.1 Topical plus systemic versus systemic 6 1115 Odds Ratio (M-H, Random, 95%
CI)
0.79 [0.56, 1.13]
4.2 Topical versus no prophylaxis 12 1735 Odds Ratio (M-H, Random, 95%
CI)
0.34 [0.21, 0.55]
5 RTIs according to quality of allocation
concealment
18 2850 Odds Ratio (M-H, Random, 95%
CI)
0.44 [0.31, 0.63]
5.1 Adequate 1 91 Odds Ratio (M-H, Random, 95%
CI)
0.18 [0.04, 0.91]
5.2 Not adequate 17 2759 Odds Ratio (M-H, Random, 95%
CI)
0.46 [0.32, 0.66]
6 RTIs according to blinding of the studies 18 2850 Odds Ratio (M-H, Random, 95%
CI)
0.44 [0.31, 0.63]
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Statistical method Effect size
6.1 Double-blind 14 2553 Odds Ratio (M-H, Random, 95%
CI)
0.52 [0.36, 0.75]





Analysis 2.1.   Comparison 2 Topical versus control, Outcome 1 Overall mortality.
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.1.1 Topical plus systemic versus systemic  
Ferrer 1994 15/51 14/50 3.75% 1.07[0.45,2.54]
Gaussorgues 1991 29/59 29/59 5.54% 1[0.49,2.06]
Hammond 1992 34/162 31/160 9.25% 1.11[0.64,1.91]
Laggner 1994 9/33 14/34 3.77% 0.54[0.19,1.5]
Lingnau 1997 9/90 17/177 3.87% 1.05[0.45,2.45]
Lingnau 1997b 13/90 17/177 3.68% 1.59[0.73,3.44]
Stoutenbeek 1996 2/49 8/42 3.1% 0.18[0.04,0.91]
Subtotal (95% CI) 534 699 32.96% 0.98[0.73,1.32]
Total events: 111 (Treatment), 130 (Control)  
Heterogeneity: Tau2=0; Chi2=7.32, df=6(P=0.29); I2=18.04%  
Test for overall effect: Z=0.14(P=0.89)  
   
2.1.2 Topical versus no prophylaxis  
Bergmans 2001 30/87 59/139 11.17% 0.71[0.41,1.24]
Brun-Buisson 1989 14/65 15/68 4.32% 0.97[0.43,2.21]
Camus 2005 32/130 34/126 9.77% 0.88[0.5,1.55]
Cerra 1992 13/25 10/23 1.88% 1.41[0.45,4.4]
Gastinne 1992 88/220 82/225 18.26% 1.16[0.79,1.7]
Georges 1994 3/31 5/33 1.64% 0.6[0.13,2.75]
Korinek 1993 22/96 17/95 4.95% 1.36[0.67,2.77]
Pneumatikos 2002 5/31 7/30 2.24% 0.63[0.18,2.27]
Pugin 1991 10/38 11/41 2.93% 0.97[0.36,2.65]
Quinio 1995 12/76 10/73 3.23% 1.18[0.48,2.93]
Rodriguez-Rolda 1990 5/14 7/17 1.53% 0.79[0.18,3.41]
Unertl 1987 5/19 6/20 1.62% 0.83[0.21,3.38]
Wiener 1995 11/30 15/31 3.51% 0.62[0.22,1.72]
Subtotal (95% CI) 862 921 67.04% 0.97[0.79,1.2]
Total events: 250 (Treatment), 278 (Control)  
Heterogeneity: Tau2=0; Chi2=5.3, df=12(P=0.95); I2=0%  
Test for overall effect: Z=0.26(P=0.8)  
   
Total (95% CI) 1396 1620 100% 0.97[0.82,1.16]
Total events: 361 (Treatment), 408 (Control)  
Heterogeneity: Tau2=0; Chi2=12.63, df=19(P=0.86); I2=0%  
Test for overall effect: Z=0.29(P=0.77)  
Test for subgroup differences: Chi2=0, df=1 (P=0.97), I2=0%  
Favours treatment 100.1 50.2 20.5 1 Favours control
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Analysis 2.2.   Comparison 2 Topical versus control, Outcome
2 Mortality according to quality of allocation concealment.
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.2.1 Adequate  
Cerra 1992 13/25 10/23 1.88% 1.41[0.45,4.4]
Stoutenbeek 1996 2/49 8/42 3.1% 0.18[0.04,0.91]
Subtotal (95% CI) 74 65 4.98% 0.64[0.27,1.52]
Total events: 15 (Treatment), 18 (Control)  
Heterogeneity: Tau2=0; Chi2=4.2, df=1(P=0.04); I2=76.21%  
Test for overall effect: Z=1.01(P=0.31)  
   
2.2.2 Not adequate  
Bergmans 2001 30/87 59/139 11.17% 0.71[0.41,1.24]
Brun-Buisson 1989 14/65 15/68 4.32% 0.97[0.43,2.21]
Camus 2005 32/130 34/126 9.77% 0.88[0.5,1.55]
Ferrer 1994 15/51 14/50 3.75% 1.07[0.45,2.54]
Gastinne 1992 88/220 82/225 18.26% 1.16[0.79,1.7]
Gaussorgues 1991 29/59 29/59 5.54% 1[0.49,2.06]
Georges 1994 3/31 5/33 1.64% 0.6[0.13,2.75]
Hammond 1992 34/162 31/160 9.25% 1.11[0.64,1.91]
Korinek 1993 22/96 17/95 4.95% 1.36[0.67,2.77]
Laggner 1994 9/33 14/34 3.77% 0.54[0.19,1.5]
Lingnau 1997 9/90 17/177 3.87% 1.05[0.45,2.45]
Lingnau 1997b 13/90 17/177 3.68% 1.59[0.73,3.44]
Pneumatikos 2002 5/31 7/30 2.24% 0.63[0.18,2.27]
Pugin 1991 10/38 11/41 2.93% 0.97[0.36,2.65]
Quinio 1995 12/76 10/73 3.23% 1.18[0.48,2.93]
Rodriguez-Rolda 1990 5/14 7/17 1.53% 0.79[0.18,3.41]
Unertl 1987 5/19 6/20 1.62% 0.83[0.21,3.38]
Wiener 1995 11/30 15/31 3.51% 0.62[0.22,1.72]
Subtotal (95% CI) 1322 1555 95.02% 0.99[0.83,1.18]
Total events: 346 (Treatment), 390 (Control)  
Heterogeneity: Tau2=0; Chi2=7.98, df=17(P=0.97); I2=0%  
Test for overall effect: Z=0.09(P=0.93)  
   
Total (95% CI) 1396 1620 100% 0.97[0.82,1.16]
Total events: 361 (Treatment), 408 (Control)  
Heterogeneity: Tau2=0; Chi2=12.63, df=19(P=0.86); I2=0%  
Test for overall effect: Z=0.29(P=0.77)  
Test for subgroup differences: Chi2=0.94, df=1 (P=0.33), I2=0%  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 2.3.   Comparison 2 Topical versus control, Outcome 3 Mortality according to blinding of the studies.
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.3.1 Double-blind  
Bergmans 2001 30/87 57/139 10.82% 0.76[0.43,1.32]
Favours treatment 100.1 50.2 20.5 1 Favours control
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Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Cerra 1992 12/25 10/23 2.04% 1.2[0.38,3.74]
Ferrer 1994 15/51 14/50 3.76% 1.07[0.45,2.54]
Gastinne 1992 88/220 82/225 18.31% 1.16[0.79,1.7]
Hammond 1992 34/162 31/160 9.27% 1.11[0.64,1.91]
Korinek 1993 22/96 17/95 4.96% 1.36[0.67,2.77]
Laggner 1994 9/33 14/34 3.77% 0.54[0.19,1.5]
Lingnau 1997 9/90 17/177 3.88% 1.05[0.45,2.45]
Lingnau 1997b 13/90 17/177 3.69% 1.59[0.73,3.44]
Pugin 1991 10/38 11/41 2.93% 0.97[0.36,2.65]
Quinio 1995 12/76 10/73 3.23% 1.18[0.48,2.93]
Rodriguez-Rolda 1990 5/14 7/17 1.53% 0.79[0.18,3.41]
Stoutenbeek 1996 2/49 8/42 3.11% 0.18[0.04,0.91]
Wiener 1995 11/30 15/31 3.52% 0.62[0.22,1.72]
Camus 2005 32/130 34/126 9.8% 0.88[0.5,1.55]
Subtotal (95% CI) 1191 1410 84.61% 0.99[0.83,1.2]
Total events: 304 (Treatment), 344 (Control)  
Heterogeneity: Tau2=0; Chi2=10.96, df=14(P=0.69); I2=0%  
Test for overall effect: Z=0.05(P=0.96)  
   
2.3.2 Open  
Georges 1994 3/31 5/33 1.65% 0.6[0.13,2.75]
Brun-Buisson 1989 14/65 15/68 4.33% 0.97[0.43,2.21]
Gaussorgues 1991 29/59 29/59 5.55% 1[0.49,2.06]
Unertl 1987 5/19 6/20 1.62% 0.83[0.21,3.38]
Pneumatikos 2002 5/31 7/30 2.25% 0.63[0.18,2.27]
Subtotal (95% CI) 205 210 15.39% 0.88[0.56,1.37]
Total events: 56 (Treatment), 62 (Control)  
Heterogeneity: Tau2=0; Chi2=0.68, df=4(P=0.95); I2=0%  
Test for overall effect: Z=0.57(P=0.57)  
   
Total (95% CI) 1396 1620 100% 0.98[0.82,1.16]
Total events: 360 (Treatment), 406 (Control)  
Heterogeneity: Tau2=0; Chi2=11.93, df=19(P=0.89); I2=0%  
Test for overall effect: Z=0.27(P=0.79)  
Test for subgroup differences: Chi2=0.26, df=1 (P=0.61), I2=0%  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 2.4.   Comparison 2 Topical versus control, Outcome 4 RTIs.
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.4.1 Topical plus systemic versus systemic  
Ferrer 1994 7/51 11/50 5.43% 0.56[0.2,1.6]
Hammond 1992 25/162 30/160 7.87% 0.79[0.44,1.42]
Laggner 1994 1/33 4/34 2.05% 0.23[0.02,2.22]
Lingnau 1997 38/90 71/177 8.24% 1.09[0.65,1.83]
Lingnau 1997b 34/90 71/177 8.21% 0.91[0.54,1.53]
Stoutenbeek 1996 2/49 8/42 3.33% 0.18[0.04,0.91]
Subtotal (95% CI) 475 640 35.13% 0.79[0.56,1.13]
Favours treatment 100.1 50.2 20.5 1 Favours control
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Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 107 (Treatment), 195 (Control)  
Heterogeneity: Tau2=0.04; Chi2=6.42, df=5(P=0.27); I2=22.13%  
Test for overall effect: Z=1.28(P=0.2)  
   
2.4.2 Topical versus no prophylaxis  
Bergmans 2001 9/87 38/139 6.75% 0.31[0.14,0.67]
Brun-Buisson 1989 3/65 6/68 3.88% 0.5[0.12,2.09]
Gastinne 1992 26/220 33/225 8.04% 0.78[0.45,1.35]
Georges 1994 4/31 15/33 4.51% 0.18[0.05,0.62]
Korinek 1993 20/96 37/95 7.54% 0.41[0.22,0.78]
Pneumatikos 2002 5/31 16/30 4.74% 0.17[0.05,0.56]
Pugin 1991 4/38 24/41 4.7% 0.08[0.02,0.28]
Quinio 1995 19/76 38/73 7.25% 0.31[0.15,0.61]
Rodriguez-Rolda 1990 1/14 11/17 2.02% 0.04[0,0.4]
Unertl 1987 1/19 9/20 2.12% 0.07[0.01,0.61]
Wiener 1995 8/30 8/31 4.98% 1.05[0.33,3.27]
Camus 2005 53/130 53/126 8.33% 0.95[0.58,1.56]
Subtotal (95% CI) 837 898 64.87% 0.34[0.21,0.55]
Total events: 153 (Treatment), 288 (Control)  
Heterogeneity: Tau2=0.44; Chi2=36.07, df=11(P=0); I2=69.5%  
Test for overall effect: Z=4.34(P<0.0001)  
   
Total (95% CI) 1312 1538 100% 0.44[0.31,0.63]
Total events: 260 (Treatment), 483 (Control)  
Heterogeneity: Tau2=0.34; Chi2=51.61, df=17(P<0.0001); I2=67.06%  
Test for overall effect: Z=4.45(P<0.0001)  
Test for subgroup differences: Chi2=7.62, df=1 (P=0.01), I2=86.88%  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 2.5.   Comparison 2 Topical versus control, Outcome 5 RTIs according to quality of allocation concealment.
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.5.1 Adequate  
Stoutenbeek 1996 2/49 8/42 3.33% 0.18[0.04,0.91]
Subtotal (95% CI) 49 42 3.33% 0.18[0.04,0.91]
Total events: 2 (Treatment), 8 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.08(P=0.04)  
   
2.5.2 Not adequate  
Ferrer 1994 7/51 11/50 5.43% 0.56[0.2,1.6]
Georges 1994 4/31 15/33 4.51% 0.18[0.05,0.62]
Pugin 1991 4/38 24/41 4.7% 0.08[0.02,0.28]
Unertl 1987 1/19 9/20 2.12% 0.07[0.01,0.61]
Brun-Buisson 1989 3/65 6/68 3.88% 0.5[0.12,2.09]
Gastinne 1992 26/220 33/225 8.04% 0.78[0.45,1.35]
Hammond 1992 25/162 30/160 7.87% 0.79[0.44,1.42]
Laggner 1994 1/33 4/34 2.05% 0.23[0.02,2.22]
Favours treatment 1000.01 100.1 1 Favours control
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Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pneumatikos 2002 5/31 16/30 4.74% 0.17[0.05,0.56]
Rodriguez-Rolda 1990 1/14 11/17 2.02% 0.04[0,0.4]
Wiener 1995 8/30 8/31 4.98% 1.05[0.33,3.27]
Bergmans 2001 9/87 38/139 6.75% 0.31[0.14,0.67]
Korinek 1993 20/96 37/95 7.54% 0.41[0.22,0.78]
Lingnau 1997 38/90 71/177 8.24% 1.09[0.65,1.83]
Lingnau 1997b 34/90 71/177 8.21% 0.91[0.54,1.53]
Quinio 1995 19/76 38/73 7.25% 0.31[0.15,0.61]
Camus 2005 53/130 53/126 8.33% 0.95[0.58,1.56]
Subtotal (95% CI) 1263 1496 96.67% 0.46[0.32,0.66]
Total events: 258 (Treatment), 475 (Control)  
Heterogeneity: Tau2=0.34; Chi2=49.49, df=16(P<0.0001); I2=67.67%  
Test for overall effect: Z=4.22(P<0.0001)  
   
Total (95% CI) 1312 1538 100% 0.44[0.31,0.63]
Total events: 260 (Treatment), 483 (Control)  
Heterogeneity: Tau2=0.34; Chi2=51.61, df=17(P<0.0001); I2=67.06%  
Test for overall effect: Z=4.45(P<0.0001)  
Test for subgroup differences: Chi2=1.2, df=1 (P=0.27), I2=16.79%  
Favours treatment 1000.01 100.1 1 Favours control
 
 
Analysis 2.6.   Comparison 2 Topical versus control, Outcome 6 RTIs according to blinding of the studies.
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.6.1 Double-blind  
Ferrer 1994 7/51 11/50 5.43% 0.56[0.2,1.6]
Bergmans 2001 9/87 38/139 6.75% 0.31[0.14,0.67]
Gastinne 1992 26/220 33/225 8.04% 0.78[0.45,1.35]
Hammond 1992 25/162 30/160 7.87% 0.79[0.44,1.42]
Korinek 1993 20/96 37/95 7.54% 0.41[0.22,0.78]
Laggner 1994 1/33 4/34 2.05% 0.23[0.02,2.22]
Lingnau 1997 38/90 71/177 8.24% 1.09[0.65,1.83]
Lingnau 1997b 34/90 71/177 8.21% 0.91[0.54,1.53]
Pugin 1991 4/38 24/41 4.7% 0.08[0.02,0.28]
Quinio 1995 19/76 38/73 7.25% 0.31[0.15,0.61]
Rodriguez-Rolda 1990 1/14 11/17 2.02% 0.04[0,0.4]
Stoutenbeek 1996 2/49 8/42 3.33% 0.18[0.04,0.91]
Wiener 1995 8/30 8/31 4.98% 1.05[0.33,3.27]
Camus 2005 53/130 53/126 8.33% 0.95[0.58,1.56]
Subtotal (95% CI) 1166 1387 84.74% 0.52[0.36,0.75]
Total events: 247 (Treatment), 437 (Control)  
Heterogeneity: Tau2=0.28; Chi2=39.32, df=13(P=0); I2=66.94%  
Test for overall effect: Z=3.5(P=0)  
   
2.6.2 Open  
Georges 1994 4/31 15/33 4.51% 0.18[0.05,0.62]
Brun-Buisson 1989 3/65 6/68 3.88% 0.5[0.12,2.09]
Unertl 1987 1/19 9/20 2.12% 0.07[0.01,0.61]
Favours treatment 1000.01 100.1 1 Favours control
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Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pneumatikos 2002 5/31 16/30 4.74% 0.17[0.05,0.56]
Subtotal (95% CI) 146 151 15.26% 0.2[0.1,0.41]
Total events: 13 (Treatment), 46 (Control)  
Heterogeneity: Tau2=0; Chi2=2.63, df=3(P=0.45); I2=0%  
Test for overall effect: Z=4.46(P<0.0001)  
   
Total (95% CI) 1312 1538 100% 0.44[0.31,0.63]
Total events: 260 (Treatment), 483 (Control)  
Heterogeneity: Tau2=0.34; Chi2=51.61, df=17(P<0.0001); I2=67.06%  
Test for overall effect: Z=4.45(P<0.0001)  
Test for subgroup differences: Chi2=5.39, df=1 (P=0.02), I2=81.43%  
Favours treatment 1000.01 100.1 1 Favours control
 
 
A P P E N D I C E S
Appendix 1. Embase.com search strategy
1. 'respiratory tract infection'/exp
2. 'respiratory tract infection':ti,ab OR 'respiratory tract infections':ti,ab
3. 'pneumonia'/exp
4. pneumon*:ti,ab
5. hap:ti,ab OR vap:ti,ab
6. bronchopneumonia*:ti,ab OR pleuropneumonia*:ti,ab
7. 'bronchitis'/exp





13. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12
14. 'intensive care unit'/exp
15. icu:ti,ab OR 'critical care':ti,ab OR 'intensive care':ti,ab OR 'burn unit':ti,ab OR 'burn units':ti,ab OR 'care unit':ti,ab OR 'care units':ti,ab
OR 'recovery room':ti,ab OR 'recovery rooms':ti,ab
16. 'critical illness'/exp





22. #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR # 21
23. #13 AND #22
24. 'ventilator associated pneumonia'/exp
25. 'ventilator associated pneumonia':ti,ab
26. #24 OR #25




31. #28 OR #29 OR #30
32. #27 AND #31
33. 'randomized controlled trial'/exp
34. 'controlled clinical trial'/exp
35. 'single blind procedure'/exp
36. 'crossover procedure'/exp
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37. random*:ti,ab OR placebo*:ti,ab OR factorial*:ti,ab OR crossover*:ti,ab OR assign*:ti,ab OR allocat*:ti,ab OR volunteer*:ti,ab OR 'double
blind':ti,ab OR 'double blinding':ti,ab OR 'double blinded':ti,ab OR 'single blind':ti,ab OR 'single blinded':ti,ab OR 'single blinding':ti,ab
38. #33 OR #34 OR #35 OR #36 OR #37
39. #32 AND #38
W H A T ' S   N E W
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H I S T O R Y
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Date Event Description
19 May 2011 New search has been performed Searches conducted
13 March 2009 New search has been performed Searches conducted.
13 March 2009 New citation required but conclusions
have not changed
One study has been included in this update (Camus 2005). Two
studies, whose data were reported in congress proceedings
(Lenhart 1994) and were unpublished (Stoutenbeek 2), have
been replaced by Krueger 2002 and Stoutenbeek 2007 which are
their published versions in peer-reviewed journals.
One study (Jacobs 1995) included in the previous version of this
review as a personal contact with the principal investigator, has
been excluded due to lack of feedback from the trial author. To
date, this study has not been published.
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